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ABSTRACT

Methods and compositions are provided for increasing or

enhancing the efficacy of antibiotics, such as by increasing
antimicrobial activity , against a variety of microbes by
co -administration with synthetic amphiphiles, including
lariat ethers and hydraphiles. Methods and compositions for
overcoming antibiotic resistance are also provided .
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MOLECULES THAT INHIBIT EFFLUX
PUMPS IN MULTI-DRUG RESISTANT
BACTERIA AND USES THEREOF

( Zgurskaya, et al., ACS Infect. Dis. 2015 , DOI:10.1021/
acsinfecdis.5b00097 ). The majority of the ESKAPE patho

CROSS REFERENCE TO RELATED

5

APPLICATIONS

This application is a bypass Continuation -In -Part (CIP )
application of International Application No. PCT/US2015/
034550, filed Jun . 5 , 2015 , which claims the benefit of U.S.
Provisional Application Ser. No. 62 /008,956 , filed Jun . 6 ,
2014 , contents of which are hereby incorporated by refer

10

ence in their entireties .

GOVERNMENT RIGHTS STATEMENT

15

This invention was made with government funding under
Grant No. CHE 1307324 , provided by the National Science

gens are Gram - negative pathogens, causing serious illness
(Nikaido , H., Science , 1994 , 264 , 382-388). Numerous
approaches have been reported for increasing antibiotic
concentration in the cell cytoplasm of efflux pump express

ing bacteria (Mahamoud , et al., J. Antimicrob . Chemoth .
2007, 59 , 1223-1229 ). For example , Phenylalanine arginyl
B -naphthylamide (PABN ) recovers levofloxacin efficacy
against Pseudomonas aeruginosa (Lomovskaay, et al., Anti
microb . Agents Chemother . 2001 , 45 , 105-116 ). However,
there is no report to date of such adjuvants that can prevent
resistance development by bacteria.
There is a need for new compounds that can act as
antimicrobials and a need for methods to recover or enhance

efficacy of existing antimicrobial agents and to combat

increasing microbe resistance to antibiotics .

Foundation (NSF ). The government has certain rights in the
invention .

20

SUMMARY

BACKGROUND

Disclosed herein are various embodiments of a method of

Certain synthetic amphiphiles are known to exhibit tox
icity to microbes such as Gram negative Escherichia coli ,

enhancing the antimicrobial activity of an antibiotic . In

(MICs ) of such synthetic amphiphiles against the various

certain embodiments, the synthetic amphiphile is a com
pound comprising one or more polar head groups in which
each polar head group comprises at least three oxygen and
hydrocarbon residues as the nonpolar elements . In certain
embodiments , the synthetic amphiphile is a lariat ether or a
hydraphile. In certain embodiments, the antibiotic and syn
thetic amphiphile are administered to the microbe such as by
contacting the microbe in culture or in solution or by
applying the antibiotic and synthetic amphiphile to a mate
rial, such as the surface of a material, in or on which the
microbe resides. In certain embodiments , the method
increases the antimicrobial activity of the antibiotic by about
2 - fold to about 40 - fold .
In certain embodiments, the synthetic amphiphile is a

certain embodiments, a method comprises administering to

Gram positive Bacillus subtilis, and the yeast Saccharomy- 25 a microbe the antibiotic with a synthetic amphiphile. In
ces cerevisiae . The minimum inhibitory concentrations
microbes depend on the microbe per se and on the structure
of the synthetic amphiphile .

Combination drugs such as amoxicillin and clavulanic

acid, sold as AUGMENTIN®, and piperacillin and tazo
bactam , sold as ZOSYN® , are effective antimicrobials.
Certain amphiphilic calixarene molecules have been pre
pared with integral antibiotic elements , but these comprise
prodrugs rather than combination therapies as described in
Bioorganic and Medicinal Chemistry 2012 , 20 , 2035-2041.
Antibiotic resistance has become a major health crisis .
Since 1940 , the increasing and sometimes frivolous use of
antibiotics has led to a dangerous level of bacterial resis

tance (a . Center for Disease Control and Prevention , Anti
biotic resistance threats in United States, 2013. b . World
Health Organization , Antimicrobial resistance global report
and surveillance , 2014 ). Bacterial resistance has been iden
tified to the all known classes of antibiotics . Cultured

30

35

40

bacteria are used to identify new antibiotics . Recently two 45
new antibiotics : teixobactin and Aspergillomarasmine A
have been invented using this technique . Antibiotics such as
teixobactin are of greater significance because it is difficult
for the bacteria to develop resistance to them .
Efflux pump function provides a general resistance

lariat ether. In certain embodiments , the synthetic amphi

phile is a lariat ether and the lariat ether comprises a

diaza -18 -crown -6 macrocycle and two linear alkyl chains
ranging in length from 1 to 20 carbon atoms, or from 1 to 22

carbon atoms. In certain embodiments, the synthetic amphi

phile is a lariat ether and the lariat ether comprises a
diaza - 15 -crown-5 macrocycle and two linear alkyl chains
ranging in length from 1 to 20 carbon atoms, or from 1 to 22
carbon atoms. In certain embodiments, the synthetic amphi
mechanism that affects multiple different classes of antibi 50 phile is a lariat ether and the lariat ether is N ,N -di-n -octyl
4,13 -diaza - 18 -crown-6 . In certain embodiments , the syn
otics ( Poole , K .; Clinic . Microbiol. Infec . 2004 , 10 , 12-26 ). thetic
amphiphile is a lariat ether and the lariat ether is
Acquisition of efflux pump based resistance usually leads to
N
,
N
di
-4,13 -diaza - 18 -crown -6 . In certain embodi
the acquisition of other types of resistance mechanisms ments, -then -decyl
synthetic
amphiphile is a lariat ether and the lariat
(target mutation and antibiotic -degrading enzymes). How 55 ether is N ,N -di-n -undecyl
-4,13 -diaza - 18 -crown-6 . In cer
ever, such mechanisms contribute independently to resis tain embodiments , the synthetic
is a lariat ether
tance development (Lomovskaya, et al ., Antimicrob . Agents and the lariat ether is N ,N -diamphiphile
n
dodecyl
4,13-diaza -18
Chemother., 2001, 45 , 105-116 ). All the efflux pumps utilize crown -6 . In certain embodiments, the synthetic
either a cation gradient (proton or sodium ) or hydrolyzes an 60 is a lariat ether and the lariat ether is N ,N '-di-n -amphiphile
ATP molecule for active antibiotic transport (McNicholas, et 4,13 - diaza - 18 - crown -6 . In certain embodimentstetradecyl
, the syn
al., J. Bacteriol., 1992 , 174 , 7926-7933 ; Levy, S. B., Anti thetic amphiphile is a lariat ether and the lariat ether does not
microb . Agent. Chemo., 1992 , 36 , 695-703). The second comprise an adamantyl group .
membrane in Gram -negative bacteria provide a reduced
In certain embodiments, the synthetic amphiphile is a
influx of antibiotics in to the cell . Hence, the antimicrobial 65 hydraphile . In certain embodiments, the synthetic amphi
resistance ( AMR ) in Gram -negative bacteria is a combina phile is a hydraphile and the hydraphile comprises the
tion of reduced influx and increased efflux of antibiotics

structure of Formula 4 :

US 10,463,044 B2
3

4
Formula 4

N

N- (CH2).

N

- (CH2)n

wherein n is 6. In certain embodiments, the synthetic amphi
phile is a hydraphile and the hydraphile comprises the
structure of Formula 4 :

N

family Enterobacteriaceae , in the family Bacillaceae , or in
the family Pseudomonadaceae . In certain embodiments, the
bacterium is Escherichia coli (E. coli ). In certain embodi
Formula 4

N- (CH2)n

N- (CH2)n

-N

wherein n is 8. In certain embodiments, the synthetic amphi- 30 ments, the microbe is a bacterium that is resistant to the
phile is a hydraphile and the hydraphile comprises the antibiotic. In certain embodiments , the bacterium is an
antibiotic resistant E. coli.

structure of Formula 4 :

Formula 4

N

N

- (CH2)n - N

- (CH2)n

wherein n is 10. In certain embodiments, the synthetic

amphiphile is a hydraphile and the hydraphile comprises the

structure of Formula 2 :

N

In the present context, antibacterial and antimicrobial are

understood to mean any compound that either inhibits or
completely arrests or prevents microbial growth or kills the

50 microbe .

In certain embodiments, the antibiotic , the synthetic
amphiphile , or both the antibiotic and the synthetic amphi
phile are administered at a concentration below their mini
spacer
spacer
R2.
R2
mum inhibitory concentrations . In certain embodiments , the
55 antibiotic is administered at a concentration below its mini
mum inhibitory concentration . In certain embodiments , the
wherein the macrocycles ( open circles) are 4,10 -diaza - 15
synthetic amphiphile is administered at a concentration
crown -5 , the spacers are n -dodecylene, and the side chains below its minimum inhibitory concentration . In certain
Formula 2

:

?»

(R2) are n -dodecyl . The diamond (middle between spacers ) embodiments, both the antibiotic and the synthetic amphi
represents a polar structural element. In certain embodi- 60 phile are administered at concentrations below their mini
ments , the polar structural element is a macrocycle. Com
mum inhibitory concentrations when determined in the
pounds 3 and 7 as shown in FIG . 10 are representative absence of the second additive. In certain embodiments, the
hydraphiles in which the polar element is not a macrocycle antibiotic is administered to a concentration of about 0.1 uM
but rather a triethyleneoxy unit or an amide -containing to about 400 uM . In certain embodiments, the synthetic
module .
65 amphiphile is administered to a concentration of about 0.1
In certain embodiments, the microbe is a bacterium . In
certain embodiments, the microbe is a bacterium in the

uM to about 400 UM . In certain embodiments, the antibiotic
is administered to a concentration of about 0.1 uM to about

US 10,463,044 B2
5

400 uM and the synthetic amphiphile is administered to a

6

FIG . 9 shows the minimum inhibitory concentration

concentration of about 0.1 uM to about 400 uM .
(MIC ) for DH5a E. coli treated with C11 lariat ether and
In certain embodiments , the antibiotic is an antibiotic rifampicin when treated with various concentrations of
selected from the group consisting of kanamycin , tobramy synthetic amphiphile and antibiotic .
cin , erythromycin , rifampicin , and tetracycline. In certain 5 FIG . 10 shows seven representative examples of chemical
embodiments, the antibiotic is an antibiotic selected from
structures of hydraphiles and hydraphile- like compounds.
FIG . 11 shows the chemical structure of TRITON X - 100 .
the group consisting of erythromycin , rifampicin , and tet
FIG
. 12 shows the correspondence between membrane
racycline . In certain embodiments , the antibiotic is kanamy thickness
and hydraphile spacer chain length as determined
cin . In certain embodiments, the antibiotic is tobramycin . In 10 by the percentage
of ions released from vesicles .
certain embodiments, the antibiotic is erythromycin . In
FIG
.
13
shows
illustrative
of lariat ether struc
certain embodiments, the antibiotic is rifampicin . In certain tures that have been preparedexamples
.
embodiments, the antibiotic is tetracycline.
FIG . 14 shows structure of hydraphiles used for investi
In certain embodiments, the microbe is E. coli, the anti gating
mechanisms of antibiotic efficacy recovery .
biotic is selected from the group consisting of rifampicin , 15 Hydraphiles
consist of three diaza- 18 -crown -6 residues con
tetracycline, kanamycin , and erythromycin , and the syn nected by alkyl
spacer chains of appropriate length . The four
thetic amphiphile is N , N -di-n -octyl-4,13 - diaza - 18 -crown-6 hydraphiles used are Cg hydraphile ( 1), C10 hydraphile (2 ),
lariat ether or N ,N -di-n - undecyl-4,13 -diaza- 18 - crown -6 C12 hydraphile ( 3 ) and C14 hydraphile (4 ).
lariat ether. In certain embodiments, the microbe is a tetra
FIGS. 15A /B /C show resistance, cytotoxicity and bio
cycline
resistant
strain
of
E.
coli
,
the
antibiotic
is
tetracy20
availability
. FIGto. minocycline
15A shows resistance
cline , and the synthetic amphiphile is a hydraphile.
developed byof hydraphiles
Tet E. coli
and C14
Certain embodiments provide for methods of treating a hydraphile . In particular, E. coli developed resistance to
microbial infection . Such methods comprise administering minocycline but did not develop resistance to C14 hydraphile
to a subject suffering from the microbial infection an effec
beyond 4 uM in 15 days . FIG . 15B shows cytotoxicity of

tive amount of a combination of an antibiotic and a synthetic 25 C8- C14 hydraphiles at MIC concentration to HEK - 293 ,

Cos-7 and HeLa cells. FIG . 15C shows bioavailability of
amphiphile as described herein .
Also disclosed herein is a method of inhibiting efflux C14 hydraphile and C12 hydraphile after Spargue Dawley
pump activity in a multi-drug resistant bacterium by admin mice were injected intravenously with 0.5 mg/kg of C14
istering to the bacterium with an amphiphile. In certain hydraphile and C , hydraphile. The bioavailability was
embodiments, the amphiphile is a compound comprising 30 observed for over 2 hours. FIG . 15D shows growth curve of
one or more polar head groups, and wherein each polar head Tetk E. coli after treatmentwith C14 hydraphile , tetracycline
group comprises at least three oxygen and hydrocarbon and their combination . In particular, C14 hydraphile at 1/2
MIC did not affect the growth of tetracycline resistant E.
residues as the nonpolar elements.
Further disclosed herein is a method of selectively coli. The growth rate in the presence of C14 hydraphile was
increasing permeability of a bacterial cell by administering 35 similar to that of tetracycline resistant E. coli by itself .
to the bacterial cell with an amphiphile. In certain embodi
Tetracycline at 220 uM had minimal effect on the growth of
ments , the amphiphile is a compound comprising one or tetracycline resistant E. coli. However, when the combina
more polar head groups, and wherein each polar head group tion of C14 hydraphile and tetracycline was used , the growth
comprises at least three oxygen and hydrocarbon residues as of tetracycline resistant E. coli was completely inhibited .
40 FIG . 15E shows Survival of HEK - 293 , HeLa and Cos -7 in
the nonpolar elements .
the presence of 1/2 MIC of Co-C14 hydraphiles. FIG . 15F
BRIEF DESCRIPTION OF DRAWINGS
shows Survival of HEK -293 , HeLa and Cos -7 in the pres
ence of 1/4 MIC of C8- C14 hydraphiles.
FIG . 1 illustrates chemical structures of N ,N -di-n -octyl
FIGS. 16A/ B show that hydraphile inhibits the activity of
4,13 -diaza - 18 -crown -6 and N ,N -di-n -undecyl- 4,13 -diaza- 45 efflux pumps and increases substrate accumulation in bac
18 -crown-6 , which are exemplified in the present disclosure .
FIG . 2 illustrates chemical structures of five antibiotics

teria . FIG . 16A shows accumulation of ethidium bromide in
the presence ofreserpine , CCCP , C8-C14 hydraphiles (4 uM )

that are exemplified in the present disclosure .
in S. aureus 1199B expressing NorA efflux pump. FIG . 16B
FIG . 3 is a graphical representation of lariat ether toxicity shows release of ethidium bromide from S. aureus 1199B
to HEK 293 cells .
50 after treatment with reserpine , CCCP , C8-C14 hydraphiles (4
FIG . 4 is a graphical comparison of N ,N -dialkyl-4,13 UM ).
diaza - 18 -crown -6 lariat ether toxicity (LD50 ) to E. coli and
FIGS. 17A /B show release of potassium ions in the

presence of C8-C14 hydraphiles. FIG . 17A shows potassium
FIG . 5 is a synthetic scheme for the preparation of effluxed from the E. coli cells in the presence of C8 -C14
N , N - di-n -octyl-4,13 - diaza -18 - crown -6 .
55 hydraphiles, DMSO (0.1 % ), gramicidin D and Valinomycin .
FIG . 6 is a graph showing the relationship between the FIG . 17B shows comparison of potassium efflux and recov
concentrations of synthetic amphiphile and antibiotic ery of tetracycline activity by C8 -C14 hydraphiles .
required to inhibit the growth of DH5a E. coli treated with
FIG . 18A shows that hydraphiles at 1/2 MIC concentration
Cg lariat ether and tetracycline .
increase permeability of Teth E. coli cells. FIG . 18B shows
FIG . 7 shows the minimum inhibitory concentration 60 permeability of HEK -293 cells at 1/2 MIC of hydraphiles .
(MIC ) for DH5a E. coli treated with Cg lariat ether and FIG . 18C shows permeability of HEK -293 cells at 2x [MIC ]
rifampicin when treated with various concentrations of of hydraphiles . In all three figures, top panel shows bright
amphiphile and antibiotic.
field (BF) images, middle panel shows the cell viability stain
FIG . 8 shows the minimum inhibitory concentration fluorescein dicatate (FDA ) and the bottom plane shows the
(MIC ) for DH5a E. coli treated with C11 lariat ether and 65 membrane permeability stain propidium iodide (PI).
tetracycline when treated with various concentrations of
FIG . 19 shows scanning electron microscopy of Cg and
synthetic amphiphile and antibiotic .
C14 hydraphile treated cells . Top panel shows the Cg
to HEK 293 cells .
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hydraphiles treated cells and bottom panel shows C14
hydraphile treated cells. Amphiphile alone column on the
left shows an image of background membrane (top ) and
hydraphile aggregate (bottom ). Hydraphiles form aggre

are known to be amphiphiles as described in Advances in
Bio - organic Frontiers ; H. Dugas, Springer Verlag: Berlin ,
1990 ; Vol. 1; pp 116-141.
Hydraphiles are synthetic amphiphiles known in the art
5 such as described in Chemical Communications 2000 , 1-9 .
gates and membrane blisters on the E. coli surface .
FIGS. 20A / B /C show that hydraphiles form aggregates , Hydraphiles are typically composed of three macrocyclic
cause membrane disruption and disrupt ion gradients. FIG . rings , separated by organic spacer elements, and terminated
various side arms. In certain embodiments, the side arm
20A shows uniform hydraphile aggregates attached to the by
can
be hydrogen attached to a nitrogen heteroatom . The
bacterial surface . FIG . 20B shows that disruption of cyto
plasmic membrane by hydraphiles forms blisters on the 10 saturated
spacer chains
can contain 1-30 carbon atoms and can be
unsaturated , linear or branched , including aro
surface of the bacteria. FIG . 20C shows that disruption of matic and orheteroaromatic
residues. The side arms can be
ion gradient caused by hydraphile leads to smoothening of linear or branched alkyl, unsaturated
alkyl, aralkyl, aryl, or
bacterial membrane.
heteroaryl and the spacer chains can contain heteroatoms
15 such as oxygen , nitrogen , and /or sulfur. Hydraphiles have
DETAILED DESCRIPTION
also been prepared that have two (e.g., 3, 7) and four (e.g.,
5 ) macrocyclic rings that function as pore - formers in bilayer
It is to be noted that the term “ a” or “ an ” entity refers to membranes
as shown in FIG . 10 .
one or more of that entity; for example, " an antibiotic” is
Amphiphiles are compounds that have both polar and
understood to represent one ormore antibiotics.Assuch , the 20 non -polar elements. A synthetic amphiphile as understood
terms“ a” (or “ an ” ), “ one or more,” and “ at least one” can be herein is a compound that contains at least one polar element
used interchangeably herein .
or " head group ” and at least one nonpolar element or " tail.”
Unless defined otherwise , all technical and scientific

TRITON X - 100 , shown in FIG . 11 , is one representative

terms used herein have the same meaning as commonly example. The compound numbered 7 in FIG . 10 is another
understood by one of ordinary skill in the art to which this 25 representative example and has two polar macrocycles and
disclosure is related .

Units ,prefixes, and symbols are denoted in their Système
International de Unites (SI) accepted form . Numeric ranges

a triethyleneoxy group that can also serve as a polar head

group .
An example of a synthetic amphiphile is the detergent
sold as TRITON X -100 (FIG . 11) in which the hydrocarbon

are inclusive of the numbers defining the range. The head
ings provided herein are not limitations of the various 30 residue is nonpolar and the oligoethylene glycol portion is
. Certain embodiments are directed to synthetic amphi
aspects of the disclosure, which can be had by reference to polar
philes such as, but not limited to , N ,N -di-n -undecyl-4,13
the specification as a whole .
diaza - 18 -crown -6 . In this compound , the 18 -membered
It has been discovered that the combination of certain
ring possesses six heteroatoms (four oxygens
synthetic amphiphiles with a range of antimicrobial agents, 35 macrocyclic
and
two
nitrogens
) that render the cyclic structure polar . The
such as antibiotics, shows unexpectedly enhanced efficacy, two 11 -carbon chains
attached to the two macrocyclic ring
increased activity , etc., of the antimicrobial agents against a nitrogen atoms are hydrophobic
and nonpolar and comprise
range of organisms, including in some cases those microbes the synthetic amphiphile's nonpolar
elements . FIG . 1 is an
that are resistant to a particular antimicrobial agent. It has illustrative example showing the chemical
structures of
further been discovered that certain hydraphiles that are too 40 N ,N '-bis(n -octyl) -4,13 -diaza - 18 - crown-6 and N ,N -bis(n
short to form ion -conducting channels surprisingly and undecyl)-4,13 -diaza - 18 -crown-6 . It is understood , however,
unexpectedly also enhanced antimicrobial activity . It was that the methods described herein are not limited to the
also discovered that anisms that are resistant to certain
synthetic amphiphiles illustrated in FIG . 1.
antimicrobial agents succumb to that antimicrobial agent
Certain aspects are drawn to a method for increasing or
when the antimicrobial agent and one or more synthetic 45 enhancing the antimicrobial activity of an antimicrobial
amphiphiles, such as those described herein , is co - adminis
agent. As used herein , the “ antimicrobial activity ” of an
tered with the antimicrobial agent.
antimicrobial agent is defined as the property of a substance
Lariat ethers are compounds known in the art as cation to inhibit the growth and reproduction of a microbial organ
complexing agents such as described in U.S. Pat. Nos. ism or to kill it . Common terms generally applied to bacteria
4,436,664, 4,474,963, 4,597,903 , and 4,687,844. Lariat 50 are bacteriostatic (stops growth ) and bactericidal (kills bac
ethers contain a macrocyclic ring and one ormore side arms teria ). Depending on the concentrations applied , microbial
as described herein . A macrocycle is a ring compound growth can be slowed or stopped in comparison to concur
comprising at least 9-members , but more typically 12 or rent experiments conducted in the absence of an antimicro
more atoms connected together.Macrocyclic rings at least as bial agent. Depending on the concentrations applied , addi
large as 60 atoms are also known in the art. Lariat ethers are 55 tional microbe death can occur in comparison to concurrent
characterized by a macrocyclic ring having from 12-48 experiments conducted in the absence of an antimicrobial
members and containing heteroatoms including, but not agent. The results of minimum inhibitory concentration
limited to , oxygen , nitrogen and sulfur. Lariat ethers possess (MIC ) evaluations and growth curves are presented herein
one or more side arms or side chains attached to the and the conditions are specified . The MIC is the lowest
macrocyclic ring . The attachment of the side chains can be 60 concentration of any agent having antimicrobial activity that
at carbon , nitrogen , or sulfur or any combination thereof inhibits the growth of a microorganism as judged by visual
within the ring . Heteroatoms such as oxygen , nitrogen , and inspection . MIC can be determined by inoculating media
sulfur can also be present in the side arms. The side armscan with the organism and adding the antimicrobial agent diluted
be linear or branched alkyl, unsaturated alkyl, aralkyl, aryl, successively in half . After an appropriate incubation time,
or heteroaryl , and heteroatoms such as oxygen , nitrogen , 65 the MIC is evaluated by inspection as the transition between
and /or sulfur can be present in or attached to the aralkyl, two successive 2 - fold dilutions in which the one concen
aryl, or heteroaryl portions of the side chains . Lariat ethers trated sample is clear and growth is apparent in the 2 -fold
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less concentrated sample . Reference herein to increasing or
enhancing activity, efficacy, potency, and the like are used
interchangeably to mean that when the synthetic amphiphile
is present, the ability of the antimicrobial agent to inhibit the
growth of or to kill an organism will be manifested at a
concentration lower than would be required to achieve the
same results in the absence of said synthetic amphiphile. In
certain embodiments, themethod increases the antimicrobial
activity of the antibiotic by : about 2 - fold to about 40 - fold ; by
about 5 - fold to about 40 -fold ; by about 10 - fold to about
40- fold ; by about 15 -fold to about 40 -fold ;by about 20 - fold
to about 40 -fold ; by about 25 -fold to about 40- fold ; by about
30 - fold to about 40 - fold , by about 35 - fold to about 40 - fold ;
or by about 40 - fold . In certain embodiments, the method
increases the antimicrobial activity of the antibiotic: by
about 2 - fold to about 48- fold ; by about 5 - fold to about
48 -fold ; by about 10 -fold to about 48 -fold ; by about 15 - fold
to about 48 - fold ; by about 20 -fold to about 48 - fold ; by about
25 -fold to about 48 - fold ; by about 30 - fold to about 48 - fold ;
by about 35 - fold to about 48 - fold ; by about 40 -fold to about
48- fold ; or by about 48 - fold . In certain embodiments , the
method increases the antimicrobial activity of the antibiotic :
by about 2 - fold to about 50 -fold ; by about 5 - fold to about
50 -fold ;by about 10 -fold to about 50 - fold ; by about 15 - fold
to about 50 -fold ;by about 20 - fold to about 50 -fold ; by about
25 -fold to about 50 - fold ; by about 30 - fold to about 50 - fold ;
by about 35 - fold to about 50 -fold ; by about 40 -fold to about
50 - fold ; by about 50 -fold , or greater than about 50 - fold .
In certain embodiments, the antimicrobial agent is an
antibiotic. The structures of five illustrative antibiotics are
shown in FIG . 2 ( i.e., kanamycin , tobramycin , erythromy
cin , rifampicin , and tetracycline ). It is understood that the
methods described herein are not limited the antibiotics
illustrated in FIG . 2. Other antibiotics are exemplified herein
and numerous other antibiotics, too numerous to list, are
contemplated . For example , the following is a brief list of
some compounds that are within the scope of the disclosure:
Carbapenems such as Imipenem , Meropenem , Ertapenem ,
Doripenem , and Biapenem ; penicillins, cephalosporins (Ce

about 0.1 uM to about 400 uM ;
about 0.1 uM to about 300 uM ;
about 0.1 uM to about 200 uM ;
about 0.1 uM to about 100 uM ;
about 0.1 uM to about 50 uM ;
about 0.1 uM to about 25 uM ;
about 0.1 uM to about 10 uM ; or
about 0.1 uM to about 1.0 uM .
In certain embodiments , the antibiotic is administered to
a concentration of:
about 0.001 uM to about 400 uM ;
about 0.01 uM to about 400 uM ;
about 0.1 uM to about 400 uM ;
about 1.0 uM to about 400 uM ;
about 10 uM to about 400 uM ;
about 100 uM to about 400 UM ;
about 200 uM to about 400 uM ;
about 300 uM to about 400 uM ;
about 0.001 uM to about 300 uM ;
about 0.01 uM to about 300 uM ;
about 0.1 uM to about 300 uM ;
about 1.0 uM to about 300 uM ;
about 10 uM to about 300 uM ;
about 100 uM to about 300 uM ;
about 200 uM to about 300 uM ;
about 0.001 uM to about 200 UM ;
about 0.01 uM to about 200 uM ;
about 0.1 uM to about 200 uM ;
about 1.0 uM to about 200 uM ;
about 10 uM to about 200 uM ;
about 100 uM to about 200 uM ;
about 0.001 uM to about 100 UM ;
about 0.01 uM about 100 uM ;
about 0.1 uM to about 100 uM ;
about 1.0 uM to about 100 uM ;
about 10 uM to about 100 uM ; or
about 50 uM to about 100 uM .
Certain aspects are drawn to a method for increasing or
enhancing the antimicrobial activity of an antimicrobial

5
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20
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35

foxitin ), glycopeptides (vancomycin ), macrolides (azithro- 40
mycin, clarithromycin ), quinolones (ciprofloxacin , naldixic
acid ), sulfamides (sulfadiazine), isoniazid , and streptomy
cin . In certain embodiments , the antibiotic is administered to
a concentration of:
45
about 0.001 uM to about 400 uM ;
about 0.001 uM to about 300 uM ;
about 0.001 uM to about 200 uM ;
about 0.001 uM to about 100 uM ;

agent by administering the antimicrobial agent in combina
tion with a synthetic amphiphile . In certain embodiments,
the synthetic amphiphile that is capable of increasing or
enhancing antimicrobial activity is a lariat ether and/or a
hydraphile . In certain embodiments, a synthetic amphiphile
is capable of reversing the resistance of a microbe to an
antimicrobial agent. In certain embodiments , the synthetic

amphiphile that is capable of reversing the resistance of a
microbe to an antimicrobial agent is a lariat ether and /or a
hydraphile. In certain embodiments , the synthetic amphi
about 0.001 uM to about 50 uM ;
50 phile is administered to a concentration of:
about 0.001 uM to about 25 uM ;
about 0.001 uM to about 400 UM ;
about 0.001 uM to about 10 uM ;
about 0.001 uM to about 300 UM ;
about 0.001 uM to about 1 uM ;
about 0.001 uM to about 0.1 uM ; or
about 0.001 uM to about 200 UM ;
about 0.001 uM to about 100 UM ;
about 0.001 uM to about 0.01 uM .
In certain embodiments, the antibiotic is administered to 55 about 0.001 uM to about 50 uM ;
a concentration of:
about 0.001 uM to about 25 uM ;
about 0.001 uM to about 10 uM ;
about 0.01 uM to about 400 uM ;
about 0.001 uM to about 1 uM ;
about 0.01 uM to about 300 uM ;
about 0.001 uM to about 0.1 uM ; or
about 0.01 uM to about 200 uM ;
60
about 0.01 uM to about 100 uM ;
about 0.001 uM to about 0.01 uM .
In certain embodiments, the synthetic amphiphile is
about 0.01 uM to about 50 uM ;
about 0.01 uM to about 25 uM ;
administered to a concentration of:
about 0.01 uM to about 10 uM ;
about 0.01 uM to about 400 UM ;
about 0.01 uM to about 300 uM ;
about 0.01 uM to about 1 uM ; or
65
about 0.01 uM to about 200 uM ;
about 0.01 uM to about 0.1 uM .
In certain embodiments, the antibiotic is administered to
about 0.01 uM to about 100 uM ;
a concentration of:
about 0.01 uM to about 50 uM ;
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about 0.01 uM
about 0.01 uM
about 0.01 uM
about 0.01 uM

to about 25 uM ;
to about 10 uM ;
to about 1 uM ; or
to about 0.1 uM .

12
membranes). The graph of FIG . 12 shows that Cg benzyl

hydraphile failed to transport irrespective of whether it was
present in DMPC, DOPC , or DEPC membranes. The Cg

benzyl hydraphile is a short- chained hydraphile and those
atoms can also be classified as short-chained hydraphiles.
The graph of FIG . 12 also shows that in the thickest DEPC
membranes, C10 benzylhydraphile is nearly inactive. Thus,

In certain embodiments , the synthetic amphiphile is 5 compounds having spacer chains shorter than eight linear
administered to a concentration of:
about 0.1 uM
about 0.1 uM
about 0.1 uM
about 0.1 uM

to about 400 uM ;
to about 300 uM ;
to about 200 uM ;
short-chained hydraphiles are those that fail to transport
10
to about 100 uM ;
cations by pore formation in the context of the organism's
about 0.1 uM to about 50 uM ;
membrane
structure. It is known from the Journal of the
about 0.1 uM to about 25 uM ;
American
Chemical Society 2002 , 124 , 9022-3 , that
about 0.1 uM to about 10 uM ; or
hydraphiles
are toxic to coli in appropriate concentra
about 0.1 uM to about 1.0 uM .
tions. Thus, C12 benzyl hydraphile killed E. coli but Cg
In certain embodiments , the synthetic amphiphile is 15 benzyl
hydraphile did not.
administered to a concentration of:
As
used
herein , a short-chained hydraphile comprises
about 0.001 uM to about 400 uM ;
spacer
chains
of such a length that they do not span the lipid
about 0.01 uM to about 400 uM ;
bilayer
of
a
particular
membrane to which the short-chained
about 0.1 uM to about 400 uM ;
hydraphiles
are
contacted
and therefore do not exhibit the
20
about 1.0 uM to about 400 uM ;
property
of
cation
transport
by pore formation. In certain
about 10 uM to about 400 uM ;
embodiments
,
a
short
chained
hydraphile has spacer chains
about 100 UM to about 400 uM ;
of
ten
or
less
linear
atoms
.
In certain embodiments, a
about 200 uM to about 400 uM ;
short
chained
hydraphile
has
spacer
chains of eight or less
about 300 uM to about 400 uM ;
linear
atoms
.
In
certain
embodiments
, a short-chained
25
about 0.001 uM to about 300 uM ;
hydraphile
has
spacer
chains
of
six
or
less
linear atoms.
about 0.01 uM to about 300 uM ;
A
general
formula
for
lariat
ethers
is
shown
as Formula 1.
about 0.1 uM to about 300 uM ;
about 1.0 uM to about 300 uM ;
about 10 uM to about 300 uM ;
Formula 1
30
R
about 100 UM to about 300 uM ;
about 200 uM to about 300 uM ;
about 0.001 uM to about 200 uM ;
R
about 0.01 uM about 200 uM ;
about 0.1 uM to about 200 uM ;
35
about 1.0 uM to about 200 uM ;
In Formula 1, the circle represents a macrocyclic ring,
about 10 uM to about 200 uM ;
which
can be composed ofheteroatoms such as O , N , and /or
about 100 uM to about 200 uM ;
S.
The
ring sizes can range from about 12 members to about
about 0.001 uM to about 100 uM ;
48
members
. The side arms (R ) can be saturated or unsatu
about 0.01 uM to about 100 uM ;
rated
alkyl
,
saturated or unsaturated aralkyl, aryl or substi
40
about 0.1 uM to about 100 uM ;
tuted
aryl
including
heteroaromatic groups. The side arms
about 1.0 uM to about 100 uM ;
can
possess
heteroatoms
such as oxygen , nitrogen , and /or
about 10 uM to about 100 uM ; or
sulfur
.
Heteroatoms
can
also
be present in groups appended
about 50 uM to about 100 uM .
to
the
aryl
or
heteroaryl
residues
. In certain of any of the
It is understood that in certain embodiments , the antibiotic embodiments disclosed herein , a lariat
ether does not com
and the synthetic amphiphile can be administered together to 45 prise
an
adamantyl
group
.
In
certain
of
any of the embodi
the respective concentrations disclosed herein .
ments
disclosed
herein
,
an
adamantyl
group
is not incorpo
In certain embodiments, a short -chain hydraphile is used rated as a terminal residue in a side chain or the
side chains

Q

to increase or enhance the potency or antimicrobial activity
of an antimicrobial agent. In certain embodiments, a short

chain hydraphile is used to reverse the resistance of a 50
microbe to an antimicrobial agent. Short- chained
hydraphiles have spacer chains of such a length that they do
not span the lipid bilayer and therefore do not exhibit the
property of cation transport by pore formation . The length
dependence was demonstrated in Chemical Communica- 55
tions 1998 , 2477-2478 . However, it is well known in the art

that the membranes ofcells havemany different components

of a lariat ether of the embodiments .

A general formula for hydraphiles is shown as Formula 2 .
Formula 2

R2.

-spacer

-spacer

-R2

and thicknesses. It was demonstrated in the Journal of the
American Chemical Society 2005, 126 , 636-642, that the

The spacers (also referred to as “ spacer chains” ) can range
from 1-30 atoms and can be linear or branched , and can be

phosphocholine (DEPC , longest fatty acid chains, thickest

appended to the aryl or heteroaryl residues . The diamond

ability of hydraphiles to transport cations depended on the 60 saturated or unsaturated . The size of the macrocyclic rings
correspondence between membrane thickness and can range from about 12 members to about 48 members . The
hydraphile spacer chain length . Thus, liposomes were side arms (R2) can be linear or branched , saturated or
formed from three different phospholipids: 1,2 -dimyristo
unsaturated alkyl, saturated or unsaturated aralkyl, aryl or
leoyl-sn -glycero -3-phosphocholine (DMPC , shorter fatty substituted aryl including heteroaromatic groups. The side
acid chains, thinnermembranes), 1,2-dioleoyl-sn -glycero -3- 65 arms can possess heteroatoms such as oxygen , nitrogen ,
phosphocholine (DOPC ), and 1,2 - dierucoyl- sn -glycero -3
and/or sulfur. Heteroatoms can also be present in groups
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(middle between spacers ) represents a polar structural ele
ment. In certain embodiments, the polar structural element is
a macrocycle . Compounds 3 and 7 as shown in FIG . 10 are
representative hydraphiles in which the polar element is not
a macrocycle but rather a triethyleneoxy unit or an amidecontaining module .
A more specific illustrative example of a lariat ether is the
structure shown in Formula 3 , where n has values from
about 0 to about 16 , or from about 4 to about 16 , and Rl is

eroaryl . When the value of “ n ” in the structure of FIG . 3 is
1, the macrocyclic ring is 4,13 -diaza - 18 -crown-6 . When R1
is saturated alkyl, the side chains can be methyl, ethyl ,

described below .

normal alkyl from n -propyl to n -eicosanyl (also called

5 sponding
n-icosanylbranched
) or branched
chain isomers thereof. The corre
chain isomers and /or unsaturated deriva
10

Formula 3

15

N - R1

R - N

20

Lariat ethers similar to Formula 3 but having 12 -mem
bered macrocyclic rings are also provided for.
The side arms (R ) of lariat ethers can be linear or
branched alkyl, unsaturated alkyl, aralkyl, or aryl, or het

25

tives are also contemplated as are various ring sizes and
heteroatom compositions including, but not limited to , O , N ,
and S. Non - limiting illustrative examples of lariat ethers
include: diaza -18 -crown-6 macrocycle with two linear alkyl
chains ranging in length from 1 to 20 carbon atoms, or from
1 to 22 carbon atoms; diaza - 15 -crown-5 macrocycle with
two linear alkyl chains ranging in length from 1 to 20 carbon
atoms, or from 1 to 22 carbon atoms; N ,N -di- n - octyl-4,13
diaza - 18 -crown-6 ; N ,N -di-n -decyl-4,13 -diaza - 18 -crown -6 ;
N ,N - di-n -undecyl-4,13 -diaza - 18 -crown-6 ; N ,N -di-n - dode
cyl-4,13 -diaza -18 -crown -6 ; and N ,N '-di-n -tetradecyl -4,13
diaza -18 -crown -6 . A representative example of a lariat ether
having a more complex structure is the compound shown as
6 in FIG . 10. Compound 6 in FIG . 10 can also be described
as a bolaamphiphile.
Formula 2 above shows a generalized structure for the
compounds known as hydraphiles. In Formula 2, R2 are the
aforementioned side arms and the term “ spacer ” designates
the linkage units that covalently connect the macrocyclic
rings.
A more specific illustrative example of a hydraphile is the
structure shown in Formula 4 , where n is the number of
methylene groups from 1-30 .

Formula 4

N- (CH2)n - N

- (CH2)n - N

50

Some non - limiting illustrative examples of hydraphiles

include : the structure of Formula 4 :

Formula 4

N

- ( CH2)n —N

N

- (CH2)n -N

N
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wherein n is 6 ; the structure of Formula 4 :

Formula 4

N- (CH2)n

N

N- ( CH2)n - N

N

N

wherein n is 8 ; the structure of Formula 4 :
Formula 4

- (CH2) n

N

(CH2)n

wherein n is 10 , 12, 14 , or 16 ; and the structure of Formula 30 ments, a combination of an antibiotic and a synthetic amphi
2:
phile as disclosed herein is administered in an effective
amount. An “ effective amount” is that amount, the admin
istration of which to a subject (also referred to as a patient),
Formula 2

R2.

?

35
spacer

spacer

-R2

either in a single dose or as part of a series, is effective for
treatment. For example , and effective amount can be an
amount that is sufficient to reduce the severity of a microbial
infection (or one or more symptoms thereof), ameliorate one
ormore symptoms of an infection , prevent the advancement

of the infection , cause regression of infection , or enhance or
wherein the macrocycles (open circles) are 4,10 -diaza - 15 40 improve the therapeutic effect(s ) of another therapy. In some
crown -5 , the spacers are n -dodecylene, and the side chains embodiments , the effective amount cannot be specified in
and can be determined by a caregiver, for example ,
(R2) are n -dodecyl, and the diamond is 4,10 -diaza- 15 advance
by
a
physician
or other healthcare provider, using various
crown -5 . Represented another way , in certain embodiments, means , for example
, dose titration . Appropriate therapeuti
the structure can be R2X - SY- S - X - R2 :wherein X cally effective amounts
can also be determined by routine
(the macrocycles ) can be 4,10 -diaza-15-crown -5, S (spac- 45 experimentation using, for example, animal models.
ers ) can be n - dodecylene, R2 (side chains ) can be n -dodecyl,
In certain embodiments , the antimicrobial agent and the
and Y (polar structural element) can be 4,10 -diaza - 15
synthetic amphiphile can be administered orally , intrave
nously, intramuscularly , intraperitoneally, by ointment,
crown - 5 .
Certain aspects are drawn to the administration of syn
cream or any other topical or surface application or surface
thetic amphiphiles with antimicrobial agents. In certain 50 coating. The antimicrobial agent and synthetic amphiphile
in a single treatment or administered
embodiments, the synthetic amphiphile is a lariat ether or a can be administered
times such as on a schedule or in a series over a
hydraphile. A combination of the antimicrobial agent and the multiple
of time. The antimicrobial agent and the synthetic
synthetic amphiphile can be administered by any route , period
amphiphile can be administered at the same time or practi
protocol, means, etc. , appropriate for its administration and cally
at the same time, such as immediate sequential admin
embodiments are not limited to any particular route, proto- 55 istration
. In certain embodiments, the antimicrobial agent
col, means, etc. of administration . For example , the antibi

and the synthetic amphiphile are pre-combined with each
other
into a composition comprising a combination of anti
microbe such as by contacting the microbe in culture or in microbial
agent and synthetic amphiphile . Thus, the antimi
solution or by applying the antibiotic and synthetic amphi crobial could
be covalently attached to the hydraphile or
phile to a material, such as the surface of a material, in or on 60 lariat ether through an ester linkage which could be cleaved

otic and synthetic amphiphile can be administered to the

which the microbe resides. Administration can be to a

by endogenous esterase or amidase enzymes. In certain
subjecthaving a microbial infection and such administration embodiments, the antimicrobial agent can be administered
to the subject results in administration to the microbe. For first followed by administration of the synthetic amphiphile .
example , the subject can be a plant or an animal. In certain In certain embodiments, the synthetic amphiphile can be
embodiments, the subject can be a mammal. In certain 65 administered first followed by administration of the antimi
embodiments, the mammal subject can be a human having crobial agent. The antimicrobial agent is considered to be
and suffering from a microbial infection . In certain embodi administered with the synthetic amphiphile so long as both
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compositions are simultaneously contacted with a microbe
even if not simultaneously applied , such as simultaneous in

Formula 5

a culture with a microbe , simultaneously on a surface with

a microbe , or simultaneously in a subject being treated . In

certain embodiments, the simultaneous presence ofboth the
antimicrobial agent and the synthetic amphiphile act
together to enhance antimicrobial activity. In certain
embodiments, the simultaneous presence of both the anti
microbial agent and the synthetic amphiphile reverse the
resistance of a microbe to the anti -microbial agent.
In certain embodiments , the synthetic amphiphile, the
antimicrobial agent, or both the synthetic amphiphile and the
antimicrobial agent are administered at concentrations
below their minimum inhibitory concentration (MIC ) val
ues
. When
certain antimicrobial
agents and, lariat
certain
antimicrobial
agents and hydraphiles
one orethers
more or
at
concentrations below their minimum inhibitory concentra
tions, are co -administered to bacteria in the family Entero
bacteriaceae ( such as but not limited to E. coli ), to bacteria
in the family Bacillaceae ( such as but not limited to B.
subtilis ), and to bacteria in the family Pseudomonadaceae
(such as but not limited to Pseudomonas aeruginosa ), the
efficacy of the antibiotic/synthetic amphiphile combination
is enhanced by as much as about 30 - fold , or by as much as
about 48 - fold , or greater compared to the activity of either
individual component. Efficacious results have been
observed in the Gram negative bacterium Escherichia coli as
the DH5a or K - 12 strain . Other strains of E. coli are
contemplated along with known strains of other Gram
negative bacteria such as Pseudomonas aeruginosa. Application to Gram positive bacteria including but not limited to
B. subtilis is also contemplated . Other bacteria and
crobes, including but not limited to Candida albicans
Trichophyton rubrum , Aspergillus, Blastomyces dermatiti
des, Cryptococcus neoformans,Mycobacterium , Klebsiella,
Enterococcus, Staphylococcus, and primitive eukaryotes
such as yeast, for example Saccharomyces cerevisiae, and
fungi, are also contemplated herein .
It has also been discovered that synthetic amphiphiles

5
R2

R2

10

15

The synthesis of compounds such as N , N '-bis(n -octyl)-4 ,
13 - diaza - 18 -crown -6 and N ,N -bis(n -undecyl)-4,13 - diaza
18 - crown-6 can readily be accomplished by methodsknown
in the art . An example is to treat 4,13 - diaza -18 -crown-6 with

an alkyl acid chloride such as n -octanoyl chloride, which in
turn can be prepared from octanoic acid and a chlorinating
agent
such as thionyl chloride (SOC12) or oxalyl chloride
20 ( CICOCOCI
). The result of this reaction is a di -tertiary
amide that can be reduced , for example , with lithium alu

minum hydride (LiAlH ) or borane (BHZ.THF). A typical
reaction is illustrated in FIG . 5. It is meant to exemplify the
approach and process but not to be in any way
25 synthetic
limiting.
In certain embodiments , lariat ether compounds can have

ring sizes that range from 12 members to 48 members . The
side chain substituents shown as R1 or R2 in Formulas 2
and/or 3 , can be normal or branched alkyl having from 1-20
30 carbon atoms, or from 1-22 carbon atoms. These substitu
ents can also be unsaturated ,multiply unsaturated , cis and /or
trans unsaturated , aralkyl, aromatic , or heteroaromatic . The
side arms can possess heteroatoms such as oxygen , nitrogen ,
and /or sulfur. Heteroatoms can also be present in groups
35 appended to the aryl or heteroaryl residues. Eighteen illus
trative structures that have been prepared are shown in FIG .
13.

In certain embodiments, the microbe is E. coli, the anti

biotic is selected from the group consisting of rifampicin ,

such as, but not limited to, lariat ethers and hydraphiles can 40 tetracycline
, kanamycin
erythromycin
, and
thetic amphiphile
is N , N , -diand-n -octyl
-4,13 -diaza
- 18 -the
crownsyn-6

be administered with an antimicrobial agent, such as an

antibiotic, to organisms resistant to the antimicrobial agent,
such that the resistant organism becomes susceptible to the
antimicrobial agent. This is referred to herein as reversing
the resistance of a microbe to an antimicrobial agent such as 45
reversing the resistance of a bacterium to an antibiotic . As
used herein , antibiotic " resistance " or the assertion that an
organism is “ resistant” to antibiotics means that some part or
all of the organism in question does not respond to the
antibiotic either by having its growth inhibited or being 50
killed . For example, the tetracycline resistant E. coli
reported herein were obtained by transformation of an E.

or N ,N '-di-n -undecyl-4,13 -diaza - 18 -crown -6 . In certain
picin , and the synthetic amphiphile is N ,N - di-n-octyl-4,13
diaza
-18 -antibiotic
crown-6 . Inis tetracycline
certain embodiments
the microbe
is E.
coli, the
, and the, synthetic
amphi
embodiments , the microbe is E. coli, the antibiotic is rifam

phile is N ,N - di- n -octyl- 4,13 -diaza - 18 -crown -6 . In certain
embodiments, the microbe is E. coli , the antibiotic is rifam
picin , and the synthetic amphiphile is N ,N -di-n -undecyl-4 ,
13- diaza - 18 - crown -6 lariat ether. In certain embodiments ,
the microbe is E. coli , the antibiotics is tetracycline, and the
synthetic amphiphile is N , N - di- n -undecyl-4,13 - diaza - 18
crown -6 lariat ether. In certain embodiments , the microbe is

coli purchased from a commercial supplier and it was found E. coli, the antibiotic is kanamycin , and the synthetic amphi
that their MIC was ~ 900 UM . This compares with the MIC phile is N ,N -di-n -undecyl-4,13 -diaza -18 -crown-6 . In cer
of 12 uM reported in Table 5 for tetracycline against E. coli. 55 erythromycin
tain embodiments
E. coli, theisantibiotic
and, the
the microbe
synthetic isamphiphile
N ,N -di-nis
This means that the tetracycline resistant E. coli requires a undecyl-4,13 -,diaza
- 18 -crown -6 .
~ 75 - fold greater concentration of antibiotic to inhibit
In
certain
embodiments
, the microbe is a tetracycline
growth .
strain of E. coli, the antibiotic is tetracycline, and
In certain embodiments, the synthetic amphiphile can be resistant
the synthetic amphiphile is a hydraphile . In certain embodi
a bis(amide) compound having the chemical structure of 60 ments, the microbe is a tetracycline resistant strain of E. coli ,
Formula 5. The size of the macrocyclic ring can range from the antibiotic is tetracycline, and the synthetic amphiphile is
about 12 members to about 48 members . The side arms can benzyl Cg hydraphile. In certain embodiments, the microbe
be saturated or unsaturated alkyl, saturated or unsaturated is a tetracycline resistant strain of E. coli, the antibiotic is
aralkyl, aryl or substituted aryl including heteroaromatic tetracycline, and the synthetic amphiphile is benzyl C14
groups. The side arms can possess heteroatoms such as 65 hydraphile .
oxygen , nitrogen , and /or sulfur. Heteroatoms can also be
To investigate the mechanism (s ) of antibiotic efficacy
present in groups appended to the aryl or heteroaryl residues. recovery, a family of crown ether based synthetic ion
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channels/hydraphiles shown in FIG . 14 were developed and
extensively studied . Since the resistance in Gram -negative
bacteria is dependent on both efflux pumps and membrane
permeability, it was hypothesized that the hydraphiles could

In certain embodiments, the amphiphile is a synthetic
amphiphile. The synthetic amphiphile can be a lariat ether or
a hydraphile. In a preferred embodiment, the synthetic

such as hydraphiles , could disrupt cation gradient and mem

Formula 4 :

overcome both of these barriers. Particularly, if amphiphiles, 5 amphiphile is a hydraphile comprising the structure of
Formula 4

- (CH2)n

- (CH2)n - N

brane integrity in bacteria , then the activity of efflux pumps
could be decreased and that of antibiotics could be recov

20

ered . Since the membranes of each bacteria and mammalian

cells have different composition , some selectivity was
expected .
In this study, hydraphiles and other membrane disruptors
are shown to significantly recover the efficacy of tetracy

25

wherein n is 8 , 10 , 12 , or 14.
In certain embodiments, the amphiphile is administered at
a concentration below its minimum inhibitory concentration .
In certain embodiments, the amphiphile is administered as
an aggregate or in a liposome.
In certain embodiments, the amphiphile is administered in
a protonated or salt form .

In certain embodiments , the bacterium is a bacterium in

cline, ciprofloxacin and norfloxacin against efflux pump the family Enterobacteriaceae, in the family Bacillaceae , or
expressing E. coli , Klebsiella pneumoniae and Staphylococ in the family Pseudomonadaceae. In a preferred embodi
cus aureus at sub -lethal concentrations. E. coli was unable 30 ment
, theorbacterium
is an bacterium
efflux pump
positive
Gram -negative
. expressing Gram

to develop resistance to the hydraphiles. In the presence of
In another embodiment, there is provided a method of
the hydraphiles, the accumulation of substrate in the cell selectively increasing permeability of a bacterial cell. This
cytoplasm increased and the efflux pump activity decreased . method comprises administering to the bacterial cell with an
. In certain embodiment, the amphiphile is a
A selective increase in the permeability of bacterial cells was 35 amphiphile
compound
comprising one or more polar head groups, and
also observed . At sub -lethal concentrations, the cytotoxicity
each polar head group comprises at least three
to mammalian cells was minimal, and there was no increase wherein
oxygen and hydrocarbon residues as the nonpolar elements.
in membrane permeability and the compound was bioavail
In certain embodiments , the amphiphile is a synthetic
able for up to 2 hours . There are no synthetic amphiphiles amphiphile. The synthetic amphiphile can be a lariat ether or
reported up to date that have recovered the activity of any 40 a hydraphile . In a preferred embodiment, the synthetic
antibiotics in the efflux pump expressing resistant bacteria. amphiphile is a hydraphile comprising the structure of
This study demonstrates , for the first time, that known

Formula 4 :

Formula 4

N

N

- (CH2)n

- (CH2)n

N

55

membrane active amphiphiles can be used to recover the

wherein n is 8 , 10 , 12 , or 14 .

antimicrobial potency by potentially inhibiting the activity
In certain embodiments, the amphiphile is administered at
of efflux pumps in bacteria and selectively increasing per a concentration below its minimum inhibitory concentration .
In certain embodiments, the amphiphile is administered as
meability of bacterial cells .
In one embodiment, there is provided a method of inhib- 60 an aggregate or in a liposome.
In certain embodiments, the amphiphile is administered in
iting efflux pump activity in a multi- drug resistant bacte a protonated
or salt form .
rium . This method comprises administering to the bacterium
In
certain
embodiments
, the bacterium is a bacterium in
with an amphiphile. In certain embodiments, the amphiphile the family Enterobacteriaceae
, in the family Bacillaceae, or
is a compound comprising one or more polar head groups, 65 in the family Pseudomonadaceae. In a preferred embodi
and wherein each polar head group comprises at least three ment, the bacterium is an efflux pump expressing Gram
oxygen and hydrocarbon residues as the nonpolar elements. positive or Gram -negative bacterium .
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The following disclosed embodiments are merely repre

TABLE 3

sentative. Thus, specific structural, functional, and proce
dural details disclosed in the following examples are not to
be interpreted as limiting.

Combination of Cu lariat ethers and antibiotics against DH5a E. coli
5

EXAMPLES

according to the procedures described in Antimicrobial

n -tetradecyl

n -hexadecyl
n -octadecyl

erythromycin
kanamycin
rifampicin
tetracycline
tobramycin

6
15

0.4
0.4
0.4
0.4

12

1.5

0.4

0.25

n -C11

12
12

1

n-C11

24

4 tetracycline

0.4
0.4

12

3

0.4

15

Fold En

hancement
20
10
10
4.
8
48
12
4

Table 4 shows the effect on the K - 12 strain of E. coli by
combining various N ,N -disubstituted - 4,13 - diaza - 18

crown -6 lariat ethers having side arms possessing six to
twelve carbon atomswith either tetracycline or rifampicin .
TABLE 4

20

Combination of lariat ethers and antibiotics against K - 12 E. coli

Amphiphile

E. coli

B. subtilis

S. cerevisiae

120

105
2.8

25
2.8

9

1.5

2.5

2.5

> 300

> 300

> 300

> 300

> 300
> 400

> 300

30

> 300
> 300
> 300
35

30
60
12
15

MIC Used

MIC

Used

(UM ) (UM ) Antibiotic

(UM )

(UM ) hancement

Cg lariat ether

Cio lariat ether
Cu lariat ether

300

12
24

Tetracycline

6

1.5 Tetracycline

6

6

6

64

Tetracycline

C12 lariat ether
Colariat ether

> 512 16 Tetracycline
> 512 250 Rifampicin

6
20

Cg lariat ether
Cg lariat ether
C10 lariat ether
Cu lariat ether

300 64 Rifampicin
300 32 Rifampicin
12 6 Rifampicin

20
20
20

24

6 Rifampicin

20

2.5
w

2.5
3
10
5
10
5
10

Fold En
2
2
2

2
4

2
4

2

Previous studies of C12 lariat ether did not show toxicity

to DH5a E. coli cells but the compound was lethal to B.
subtilis and to S. cerevisiae at minimum inhibitory concen

trations (MICs ) of 2.5 uM . The MICs of C6, C3, C10 , C119

Table 2 shows the effect of combining rifampicin or
tetracycline with N , N -bis (n - octyl) -4,13 -diaza - 18 -crown -6

and then exposing the E. coli to the combination . Note that
DMSO is the standard abbreviation for dimethylsulfoxide.
TABLE 2

Combination of Cg lariat ethers and antibiotics
against DH5a E. coli

MIC Used

MIC

Chain
n -Co
n -Co
n -Cg
n -Cg

(UM ) (UM ) Antibiotic

(UM ) (UM ) DMSO

> 120
> 120
> 120

80 rifampicin
60 rifampicin
40 rifampicin

64
64
64
12

> 120
> 120
> 120
> 120
> 120

80
60
40
30
20

12
12
12
12
12

> 120 100 tetracycline
tetracycline
tetracycline
tetracycline
tetracycline
tetracycline

Used

vol- %

Fold En

hancement

1

0.4

3 + 1
3 + 1
2
2

0.4
0.4
0.4
0.4
0.4
0.4

3

50.6

4

12

0.4

0

3

0.25
0.5

and C14 lariat ether to DH5a E. coli were determined to be
40 > 360 uM , > 240 uM , 12 uM , 24 uM and > 360 uM respec
tively . Peak transport activity was observed for C10 lariat
ether, which was themost toxic compound in the MIC study .
Two -armed Cg and Ch lariat ethers have also been shown to
enhance the efficacy of rifampicin and tetracycline in DH5a
45 E. coli . Here we have performed toxicity studies of lariat
ethers to human embryonic kidney HEK - 293 cells to deter
mine the selectivity of the lariat ethers between mammalian
and bacterial cells .

Side

n -Cg
n -C8
n -Cg
n -Co
n -C8

3
6

60
60

18 tetracycline

25

11
24
> 300

60
60

16 tetracycline
12 tetracycline

MIC (UM )

n -octyl
n -decyl
n -undecyl
n -dodecyl

18 rifampicin
16 rifampicin
12 rifampicin
8 rifampicin

24

Minimum Inhibitory Concentrations for Synthetic
Amphiphiles and Antibiotics
in Formula 3

24
24
24

24

vol- %

24
24

TABLE 1

Antibiotic or R1

Used

(UM ) (UM ) DMSO

n -C11

Laboratory Standards Institute , 2012 ; Vol. 32, 67 pp . MIC

values so determined for several lariat ethers and for several
antibiotics are shown in Table 1 .

MIC

10 n -Cu

latter being an E. coli strain possessing the tet - A efflux
pump. Experiments were conducted to determine the MIC
values for the synthetic amphiphiles known as lariat ethers

M07 -A9: Methods for Dilution Antimicrobial Susceptibility
Tests for Bacteria that Grow Aerobically ; Clinical and

MIC Used

nn --C11
C11
n-C11
n-C11

Among the organisms studied are several strains of the

bacterium E. coli. These include, but are not limited to ,
DH50 , JM109, K - 12 , and tetracycline -resistant E. coli, the

Side

Chain (UM ) (UM ) Antibiotic

21
21
21
48

24
6
6

The toxicity of C., Cg, C10, C11 and C14 lariat ethers to

50 HEK - 293 cells was determined by using an MTT assay.

Results are presented in FIG . 3 , in graphical form for the
percentsurvivalofHEK -293 cells in the presence of various
concentrations of lariat ethers. The abscissa is a logarithmic

scale for the concentrations ranging from 1 uM to 1000 uM
55 (1 mM ) used in the experiment. The ordinate represents
percent survival of HEK -293 cells . For Cg and C11 lariat
ether, concentrations equivalent to half MIC to E. coli , i.e.

60 uM and 12 respectively, were also tested for toxicity to
60
FIG . 3 shows the percent survival of HEK - 293 in the
Table 2 also shows the effect of combining tetracycline presence of various concentrations of lariat ethers . The
with N ,N -bis (n -octyl)-4,13 -diaza- 18 -crown-6 and then ordinate ranges from 0-100 % and records the survival of
exposing the E. coli to the combination . The MIC of human embryonic kidney (HEK -293 ) cells when exposed to
tetracycline decreases in the presence of DMSO .
concentrations ( 1 uM to 1 mM ) of lariat ethers having linear
Table 3 shows the effect of combining rifampicin or 65 side arms ranging from six to fourteen carbon atoms.
tetracycline with N.N '-bis(n -undecyl)-4,13 - diaza - 18
As seen in FIG . 3 , with the increase in concentrations of
crown -6 and then exposing the E. coli to the combination . lariat ethers , the percent survival decreases. HEK -293 cells
HEK - 293 cells .
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have 90 % survival in the presence of 0.5 % DMSO . Hence ,
the ~ 90 % survival of HEK - 293 cells in the presence of 1 uM
Cg and Chi lariat ethers is attributed to the toxicity ofDMSO
(within experimental error as reflected in the error bars ). C14

antimicrobial agents if their spacer chains [ - ( CH2)n- ]
contained 8 or fewer methylene groups. It was unexpectedly
discovered that the short hydraphile benzyl Cg significantly
enhanced the potency of several antibiotics.
lariat ether is considered non -toxic even at 1 mM ( 1000 uM ) 5 Studies with a tetracycline-resistant strain of E. coli ,
specifically tetracycline -resistant JM109, have shown that
because 45 % survival of HEK -293 is observed .
lariat ethers produce significant enhancements of antimicro
Two commonly used abbreviations are LD50 and IC 50
potency. A JM109 strain that is highly resistant to the
The former is the concentration of an agent that comprises bial
antibiotic
was studied in the presence of various
a lethal dose to 50 % of the organism under study. The latter lariat etherstetracycline
at different concentrations. As shown by the data
is the concentration of agent that inhibits growth of 50 % of 10 in Table 6 , the
antimicrobial resistance was reversed . Table
the organism under study. The data presented and graphed in 5 shows the results
for the tetracycline- resistant JM109
FIG . 4 represent the averaged (multiple replicates ) LD50
strain
of
E.
coli
in
the
presence of lariat ethers.
concentrations of C., C3, C10 , C12 , and C14 lariat ethers
against HEK -293 cells . It also shows the inhibitory concen
TABLE 5
tration (IC50 ) for each compound to DH5a E. coli cells. The 15
abscissa represents the number of (CH2) groups in spacer
MIC values for synthetic amphiphiles or
antimicrobials against tetracycline resistant E. coli
chains. The ordinate is logarithmic and reflects the concen
trations (in uM ) of the various lariat ethers used . The MIC
Amphiphile
Antimicrobial
MIC (UM )
values ofCo and C14 lariat ethers are greater than 360 uM but
None
for the purpose of graphical presentation , the IC50 values are 20
250 + 10
Cg hydraphile
None
35 + 5
C10 hydraphile
considered at 180 ° M . At 180 uMC and C14 lariat ethers are
None
5 + 0.5
C12 hydraphile
inactive against E. coli .
None
2 + 0.125
C14
hydraphile
FIG . 4 shows the toxicity of various side chain length
None
> 512
C6 lariat ether
lariat ethers to HEK -293 and DH5a E. coli. In FIG . 4 , the
120
None
Cg lariat ether
16
None
open circles (dashed line ) represent the average LD50 to 25
C10 lariat ether
None
24
C11 lariat ether
HEK - 293 cells whereas the squares (solid line ) represent the
None
> 512
C12
lariat
ether
IC50 to E. coli . The IC50 for Cg lariat ether to E. coli (150
900 + 50
None
Tetracycline
> 1000
Ampicillin
uM ) is much higher than the LD50 to HEK -293 ( 33 uM ). The
None
IC50 for C111 lariat ether to E. coli ( 12 uM ) is lower than the
LD so to HEK -293 ( 22 ?M ). The synergy experiments for Cg 30 Studies with several strains of E. coli have shown that
and Cii lariat ethers were performed at 60 uM and 12 uM , lariat ethers produce significant enhancements of antimicro
respectively. In the presence of 60 uM Cg lariat ether, 27 %
potency . In particular, a study of tetracycline- resistant E.
survival of HEK - 293 cells was observed . In the presence of bial
coli
showed that in the presence of lariat ethers , the antimi
12 UM Cii lariat ether, 66 % survival of HEK - 293 cells was
observed. With the increase in side chain length of lariat 35 for
crobial
resistance
Datatetracycline
are shown ofin tetracy
Table 6
treatment
with was
lariatreversed
ethers .and
ethers, the IC 50 to E. coli is observed to be lower than LD50
cline - resistant strains of E. coli .

to HEK -293 . This data suggests that with an increase in side

chain length , the toxicity of lariat ether to HEK - 293 is lower
than that to E. coli . Similar to the toxicity trend in E. coli ,
C10 lariat ether had the highest toxicity to HEK -293 .
Minimum inhibitory concentrations were determined
using protocols described above for various synthetic
amphiphiles and antimicrobials against DH50 , K - 12 , and
tetracycline-resistant strains of E. coli. The data are sum
marized in Table 5. N ,N -Dibenzyl-4,13 - diaza - 18 -crown -6 is
referred to in the table as dibenzyldiaza -18 - crown -6 . The
compounds referred to as Cg benzyl hydraphile and C14
benzyl hydraphile have the structures shown in Formula 4 ,
in which “ n ” is 8 and 14 , respectively.
Initial studies ofhydraphile -enhanced antimicrobial activity were conducted with three hydraphiles. These are illus
trated in Formula 4 , in which “ n ” = 12 , 14 , and 16. In several
published studies, it was found that hydraphiles having
spacer chains [ (CH2)n- ] in the 12-16 range were invari
ably the most active ion transporters. These results can be
found in the following articles: Chemical Communications
1998, 2477-2478 and Journal of Supramoleular Chemistry
2001, 1, 23-30 . It was discovered that hydraphiles that
successfully formed ion channels in membranes also killed
E. coli, as reported in the Journal of the American Chemical
Society 2002, 124 , 9022-9023. In this report , the hydraphile
having (CH2)8 spacers did not exhibit toxicity to E.
coli ,whereas the benzyl C 2 hydraphile having (CH ) 12—
spacers killed the bacteria .
All previous studies, both biophysical and biological,
indicated that hydraphiles of the general type shown in
Formula 4 would be inactive on their own or as adjuncts to

TABLE 6
40

Combination of lariat ether and tetracycline against
tetracycline resistant E. coli

MIC

Amphiphile

45 Colariat ether
Cg
lariat ether
Cg lariat ether
Cg lariat ether
C10 lariat

Used

MIC

Used

Fold En

(UM ) (UM ) Antibiotic
(UM ) (UM ) hancement
2
> 512 192 Tetracycline
900
413
120
87
10
80 Tetracycline 900
120
120
16

ether

50 ether
C1o lariat

16

Cu lariat

24

Cu lariat

24

Cu lariat
55 ether

24

Cu lariat
ether
C12 lariat

24

ether
ether

> 512

60 Tetracycline
40 Tetracycline
6
9
18
16
12
8

Tetracycline
Tetracycline
Tetracycline
Tetracycline
Tetracycline
Tetracycline

192 Tetracycline

900

175
233

225

5
4
4

900

56

16

900

87

10

900

87

10

900

87

10

900

175

5

900

450

2

900
900

ether

60

Studies with several strains of E. coli have shown that

hydraphiles produce significant enhancements of antimicro
bial potency. In particular, a study of tetracycline-resistant E.
coli showed that in the presence of hydraphiles , the antimi
65 crobial resistance was reversed . Data are shown in Table 7
for treatment with hydraphiles and tetracycline of tetracy
cline -resistant strains of E. coli.
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TABLE 7

icity issues . Recovery of antimicrobial efficacy by
hydraphiles could make this infection treatable .

Combination of hydraphile and tetracycline against

As seen in the following examples, hydraphiles could

tetracycline resistant E. coli

MIC

Amphiphile
Cg hydraphile
Cg hydraphile

Used

(UM ) (UM ) Antibiotic
Tetracycline
250 125
250
62.5 Tetracycline
C10 hydraphile 35 17.5 Tetracycline

MIC Used Fold En

inhibit the activity of efflux pumps and increase the accu

5 mulation of substrate (antibiotics) in the cell cytoplasm . This

efflux pump inhibition by hydraphiles is indirect as observed
with CCCP rather than direct inhibition as observed with
PABN or reserpine. One advantage of such an approach is
23
thatbacteria cannot easily develop resistance to amphiphiles
5
8.75 Tetracycline
C10 hydraphile 35
10
that
transport ions and disruptmembranes. A single mutation
5
16
2.5
Tetracycline
C12 hydraphile
in the amino acid chain of an efflux pump peptide can render
5
2
1.25 Tetracycline 900
C12 hydraphile
2
1
4
Tetracycline 900
C14 hydraphile
molecules such as reserpine and PABN useless. It is shown
2
3
C14 hydraphile
0.5 Tetracycline 900
here that E. coli cannot develop resistance to hydraphiles for
over 15 days .
inhibition of efflux pumps by hydraphiles is caused
The synthetic amphiphile shown as Compound 6 in FIG . 15 by The
disruption of ion gradients and /or membrane integrity .
10 was examined with two E. coli strains : K - 12 and the
However, this raises the issue of cytotoxicity and bioavail
tetracycline resistant strain . In the presence of tetracycline ability
. Preliminary results show that hydraphiles were bio
and in the absence ofa synthetic amphiphile , the MIC values available
through IV for over 2 hours . Cytotoxicity of
against
K
12
and
the
tetracycline
resistant
strain
were
6uM
20
hydraphiles
at sub-MIC concentrations was minimal.
and 900 uM , respectively . For the K - 12 strain , addition of
Overall
,
disclosed
herein is a non -resistant adjuvant plat
Compound 6 in FIG . 10 at a concentration of approximately form that could be used
with novel molecules to recover
half its MIC , in the presence of tetracycline , altered the MIC antimicrobial potency against life-threatening bacterial
of tetracycline from 6uM to 2 uM . This is an approximately infections.
three -fold increase in efficacy. For the tetracycline-resistant 25
strain , addition of compound 6 in FIG . 10 at a concentration
Example 1: N.N '-Di- n - octyl- 4,13-diaza - 18-crown-6
of approximately half its MIC , in the presence of tetracy
cline , altered the MIC of tetracycline from 900 uM to 150
This compound was prepared by methods known in the
UM . This is an approximately six -fold increase in efficacy . art . 4,13 -Diaza - 18 -crown -6 was acylated with octanoyl
(UM ) (UM ) hancement
900
900
900
900
900

30
82
40
200
55
400
220
360

30
11

Referring to FIGS. 6 through 9 which show plots of 30 chloride and the resulting diamide was reduced with

antibiotic concentration as a function of lariat ether concen

tration for the antibiotics tetracycline and rifampicin with Cg
and C11 lariat ethers. FIG . 6 is a graph showing the rela
tionship between the concentrations of synthetic amphiphile
and antibiotic required to inhibit the growth of E. coli treated 35
with Cg lariat ether and tetracycline. FIG . 7 is a graph
showing the relationship between the concentrations of
synthetic amphiphile and antibiotic required to inhibit the
growth of E. coli treated with Cg lariat ether and rifampicin .
FIG . 8 is a graph showing the relationship between the 40
concentrations of synthetic amphiphile and antibiotic
required to inhibit the growth of for E. coli treated with Cui
lariat ether and tetracycline . FIG . 9 is a graph showing the
relationship between the concentrations of synthetic amphi
phile and antibiotic required to inhibit the growth of E. coli 45
treated with C11 lariat ether and rifampicin . Graphical rep
resentations are known to those in the art as a means to
assess whether a combination of drugs is additive or syner
gistic as described in Drug Synergism and Dose - Effect Data
Analysis ; Chapman & Hall : Boca Raton , 2000 , 267 pp . 50
Hydraphiles and other synthetic amphiphiles have been
known for decades. The majority of the studies with these
molecules have been focused on the development of new
structures and their effect on ion transport. Many studies
have also reported their activity as antibiotics, which is 55
greater against Gram -positive bacteria . The present study
reports for the first time that synthetic amphiphiles could be
used to recover the efficacy of antibiotics against efflux
pump expressing and multi drug resistant bacteria or “ Super
bugs”. The study as illustrated in the examples below show 60
that hydraphiles could recover the activity of tetracyclines
and fluoroquinolones against two Gram negative and one
Gram positive bacteria . One of these bacteria is K. pneu
moniae , which was isolated from a patient, and is an urgent
threat to public health . This bacterium is resistant to almost 65
all known classes of antibiotics and the last resort of
treatment is Colistin . However, Colistin does have cytotox

B2H..THF. Short path distillation afforded the lariat ether

(63 % ) as a colorless oil (bp 181-190 ° C., 0.04 torr ).
Example 2 : Determination of Minimum Inhibitory
Concentrations (MIC )

Minimal Inhibitory Concentration (MIC ) Procedure . The
steps used in the experimental determination of the mini
mum inhibitory concentration (MIC ) are recorded below .

1. Streak the E. coli (DH5a or K - 12 MG1655 ) strain on L.B
agar plates . For tetracycline resistant E. coli use L.B.
agar +ampicillin plates ( 150 uM ).
2. Inoculate a 2 mL of L.B.Miller media with one colony of
bacteria and incubate overnight at 37 ° C. and 200 rpm .
For tetracycline resistant E. coli, use 128 uM ampicillin in
L. B. Miller media .

3. Prepare an excel file outlining the concentrations and

volumes of compound and L.B.Miller media required to

be added to each test tube . Note : The total volume of

media is 2000 uL in each test tube.
required .
5. Dilute from the initial concentration according to the
required concentration of the compound. Note : For com
pounds that are dissolved in DMSO , dilutions must be
made in a way that the volume of DMSO added to each
test tube is kept constant at 5 uL (0.25 % by volume). For
compounds that are dissolved in water, the volume of
water added to media is constant at 5 (0.25 % by volume).

4. Prepare initial concentration of all the compounds

6. Add the appropriate volume of media to each test tube.
7. In a separate test tube, knock back E. coli to optical
density (N = 600 nm , O.D .)= 0.100 by adding 50 uL of E.
coli to 1950 uL of L.B. Miller media. Check O.D. every
30 minutes until the E. coli grows to O.D.= 0.600 .
8. While the E. coli grows, add the appropriate volume of
compound to each test tube. Vortex each test tube for 2-3
seconds.
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were monitored for confluence and growth medium was
replaced every 48 h , until cells were placed onto a 96 -well

9. Add 20 uL E. coli grown to O.D.= 0.600 to each sample .
Note : Manage experiments so that E. coli is grown to
O.D. = 0.600 before adding to each test tube .

plate for toxicity studies .
After reaching 80-90 % confluence , cells were trypsinized
11. Inoculate test tubes at 37° C. and 200 RPM for 24 hours. 5 and suspended in media containing DMEM and 10 % FBS
Results are determined by visual verification or O.D. (no antibiotics). The cells were counted on a hemacytometer
(a =600 nm ) measurement of the growth or no growth and plated at a density of 20,000 cells per well in a 96 -well
plate and grown for 24 hours to reach 60-70 % confluence .
of bacteria .
DMSO stocks of C. , C3, C10, C11 and C14 diaza - 18 -crown -6
Example 3 : Tetracycline Efficacy Recovery Study
10 lariat ethers were prepared at 200 mM and diluted 1:10 to get
working concentrations of 20 mM , 2 mM , and 0.2 mM . Each
with N , Nº- Di-n -Octyl-4,13 - Diaza- 18 - Crown -6
stock solution was further diluted 1: 100 into DMEM supple
mented
10 % FBS to get final concentrations of 1 mM ,
This study was conducted with N , N -di-n -octyl-4,13 - di 0.1 mm with
, 0.01 mM (10 uM ) and 0.001 mM ( 1 The original
aza -18at-crown
-6 (Cg lariatof ether
was pre- 15 media was then removed from the cells and replaced with
pared
a concentration
20 mM). Ainstock
DMSOsolution
. A tetracycline
200 uL media containing the desired concentration of com
stock solution was prepared at a concentration of 1 mM in pound
Three wells were used for each concentration pro
Milli -Q H20 . An 80 uM solution of Cg lariat in media was viding. experimental
. As a positive control for
prepared by adding 8 uL of C , lariat stock solution ( 20 mM ) growth , three wells triplicates
containing cells were treated with
to 2 mL media. Preparation of 60 uM , 40 uM , and 20 uM 20 DMEM supplemented with 10 % FBS . For DMSO control,
solutions of Cg lariat, 6 uL , 4 ul , and 2 uL of Cg lariat stock three wells containing cells were treated with DMEM
solution ( 20 mM ) was added to 2 mL media respectively and supplemented with 10 % FBS and 0.5 % DMSO . As a nega
to make the volume of DMSO the same (0.4 vol- % with tive
wells without cells were treated with DMEM
respect to media ) appropriate volume of DMSO was added supplemented with 10 % FBS and 0.5 % DMSO . The 96 -well
(2 , 4 , and 6 of uL DMSO respectively ).
25 plate was then returned to 37° C. and 5 % CO2 for 24 hours.
After incubation , MTT assay (Sigma- Aldrich ) was per
Example 4 : Co- Administration of Antibiotics and
formed according to manufacturer's protocol. The absor
Lariat Ethers to E. coli. Cg Lariat (MIC = 120 uM )
bance was measured at 570 nm and nonspecific absorbance
and Tetracycline Against E. coli DH5a (MIC = 10
was corrected at650 nm , using SpectraMax340 micro plate
30 reader.
UM )
The experiment was performed in triplicate and the aver
Each concentration of Co-lariat was tested with different age ofpercent survival of three experiments was determined .
The graph in FIG . 3 represents the percent survival with
concentrations of tetracycline (from 6 uM to 0.25 Tetracy
10. Vortex each test tube for 2-3 seconds .

cline was dissolved in water. The volume of water added was

increasing concentration of lariat ethers on a logarithmic

between 12 to 0.5 uL . The volume ofwater added was not 35 scale . The error bars represent the standard error. The lethal
50 (LD50) for each compound was calculated by using
constant but the volume of media was changed so that the dose
the
equation
for a logarithmic regression curve. The R2 value
total volume was kept constant at 2 mL .
for each curve was approximately 0.9 .
Example 5 : Procedure for Assessment of Potential

Antibiotic Synergy

1. Steps 1-7 , described in the MIC procedure , shown in
Example 2 , were followed .

40

Example 7 : Compounds and Bacteria Used in

Mechanism Study

This study involved the use of C8, C1 , C12 and C14

hydraphiles (compounds 1-4 as shown in FIG . 14 ). All the

2.pound
While was
the E.added
coli togreweach, thetestappropriate
volume of com- 45 hydraphiles have two distal benzyl groups. Antibiotics tet
tube .
3. Antibiotics were added at the required volume of solution

racycline and ciprofloxacin were used in this study. Grami

cidin D , valinomycin and Triton X - 100 were used as con
to obtain the desired concentration in each test tube. The
trols to compare the activity of the above hydraphiles to that
concentration of each compound was adjusted so that the ofknown protein ion channel, a protein ion carrier, or simply
total volume of DMSO added to each test tube was 5 uL 50 a detergent. Known efflux pump inhibitors such as reserpine
(0.25 % by volumewith respect to final volume i.e. 2000 and CCCP were also used . All the antibiotics and controls
were acquired from Sigma- Aldrich and were used as
i.e. 2 mL ).
received .
4. Each test tube was vortexed for 2-3 seconds .
5. Steps 10-12 from the MIC procedure , shown in Example
To test the hypothesis that the hydraphiles could over
2 , were then executed .
55 come the efflux pumps and membrane permeability barriers
in Gram -negative bacteria, a strain of Escherichia coli
Example 6 : Determination of Toxicity of Lariat
resistant to tetracycline and ampicillin ( TetÃ E. coli ) was
Ethers to HEK -293 and E. coli Cells
developed . Tetracycline resistance in Tet E. coli is caused
by the tetA [class C ] gene that encodes a tetracycline specific
Growth medium containing DMEM with high glucose 60 efflux pump (tetA ) spanning the cytoplasmic membrane
( ATCC ), 10 % fetal bovine serum (FBS; Sigma-Aldrich ) and (Sapunaric and Levy ; Substitutions in the interdomain loop

10 ug/mL of blasticidin (Thermo-Fischer) was prepared .

of the Tn10 TetA efflux transporter alter tetracycline resis

HEK 293 cells were thawed out from cryo - preserved tance and substrate specificity, Microbiol. 2005 , 151, 2315
samples in 10 mL growth media , centrifuged at 500 rpm for 2322 ; Thanassi, et al., Role of outer membrane barrier in
10 minutes to remove preservative. The cells were then 65 efflux -mediated tetracycline resistance of Escherichia coli.
resuspended in fresh growth medium and cultured using a J. Bacteriol., 1995 , 177 , 998-1007 ). K. pneumoniae (ATCC
T -75 flask ( Thermo-Fischer) at 37 ° C. and 5 % CO2. Cells BAA 2146 ; another Gram -negative bacterium ) that
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expresses multiple classes of efflux pumps and NDM - 1 gene
was also used . This K. pneumoniae is a clinically relevant
strain that was isolated from a patient. Gram -positive S.
aureus 1199B was used that overexpresses the NorA efflux
pump. Since ethidium bromide and norfloxacin are the
substrates of efflux pumps , S. aureus 1199B was used to
evaluate the activity of efflux pumps in the presence of the
hydraphiles and other membrane disruptors .
Example 8 : Antimicrobial Activity
The minimal inhibitory concentrations (MIC ) of all the
compounds against three bacterial strains were first deter
mined using the microtiter technique as described above .
Inhibition greater than 80 % was considered as the MIC
( Table 8 ). C14 and C12 hydraphiles that could span the
bilayer showed the lowest MICs , whereas C1o and Cg
hydraphiles were less active as antimicrobials. All four
hydraphiles were more active against Gram - positive bacte
ria . The MIC ofC14 hydraphile against E. coli was 2 uM and
against S. aureus at 1 uM . The MIC of C12 hydraphile was
lowest against S. aureus at 0.5 uM . C14 hydraphile had a
MIC of 10 uM against K. pneumoniae that was reported to
be resistant to 34 different antibiotics. Antimicrobial prop
erty of hydraphiles is attributed to the disruption of ion
homeostasis in bacteria .MICsof antibiotics against all three
strains were as expected . Tet? E. coli was resistant to
tetracycline (900 ?M ) and Ampicillin (> 1000 · M ) but
sensitive to other antibiotics tested ( Table 9). S. aureus
1199B was resistant to ethidium bromide (MIC ),norfloxacin
and ciprofloxacin (MIC ) but sensitive to others.
TABLE 8
Minimal Inhibitory Concentrations (MIC )

Compounds
used

K.

E. coli

pneumoniae

(Tet *)

200
56
35
10

250
2

1

1000

900
0.5
56

N.D.
N.D.

Cg hydraphile
C10 hydraphile
C12 hydraphile
C14 hydraphile
Tetracycline
Ciprofloxacin

N.D.
N.D.

Reserpine

1199B

128

35
5

700

CCCP

S. aureus

8

0.5

54
> 128

> 128

N.D. — Not determined

Example 9 : Combination Studies
Hydraphiles have been shown to transport ions through
liposomes and mammalian cells and inhibit bacterial
5 growth .However, the bacterial strains used herein are mul
tidrug resistant and the effect ofhydraphiles on the inhibition
of resistance mechanism (efflux pumps ) was notknown. The
hydraphiles and the controls were tested next to see whether
they could recover the activity of antibiotics against efflux
10

pump expressing Gram -positive and Gram - negative bacte
of 1/2 [MIC ] or 1/4 [MIC ] of each hydraphile or the controls
ria . The MIC of antibiotics were determined in the presence

used .

The results show that at 1/2 [MIC ] and 1/4 [MIC ] of C8 -C14
15 hydraphiles
, the activity of tetracycline against Tet" E. coli
was recovered . At 1/2 [MIC ], Cg hydraphile recovered the
activity of tetracycline by 30 - fold , Cio hydraphile by
23 - fold , C12 hydraphile by 16 - fold and C14 hydraphile by
20 4 - fold ( Table 9 ).When the concentration of hydraphiles was
kept constant at 1 uM , a chain length dependent trend was
clear (FIG . 15E ). C14 and C12 hydraphiles that could span
the membrane were more effective than C , and C10
hydraphiles. Similar results were observed with tetracycline
25 and ciprofloxacin recovery against K. pnuemoniae and nor
floxacin recovery against S. aureus 1199B . The activity of

tetracycline was recovered by 40- fold and ciprofloxacin by

10 - fold against K. pneumoniae ( Table 10 ). Ampicillin activ
ity
was not recovered by C14 hydraphile against E. coli or K.
30 pneumoniae . This indicates a mechanism of antibiotic effi
cacy recovery specific to the inhibition of efflux pump
activity .
Synergy between hydraphiles and tetracycline was con
35 firmed using growth curve and checkerboard experiment
(FIG . 15D ). In the presence of 1/2 [MIC ] of C14 hydraphiles ,
the lag phase was extended by ~ 60 minutes. These could be
due to either the activity of hydraphiles as ion channels
causing disruption of ion gradient homeostasis or due to
antimicrobials
activity causing cell death . However, the
40
growth of E. coli recovered completely and growth rate was
the same as that of E. coli alone. In the presence of
tetracycline, there was some inhibition of growth observed
but when 1/2 [MIC ] hydraphile or 1/4 [MIC ] tetracycline was
combined with tetracycline , growth is completely inhibited
45
for over 24 hours. This shows a synergy between C14
hydraphiles and the antibiotics .

TABLE 9

Recovery of tetracycline activity against Tet* E. coli by

TABLE 10
Recovery of tetracycline activity against K. pneumoniae by

50

hydraphiles

hydraphiles

Amphiphile
used

No amphiphile
Cg hydraphile
Cg hydraphile
Cg hydraphile
C10 hydraphile
C10 hydraphile
C10 hydraphile
C12 hydraphile
C12 hydraphile
C12 hydraphile
C14 hydraphile
C14 hydraphile
C14 hydraphile

Fold

[Amphiphile ]

Antibiotic

UM

used

1

62.5 (1/4 [MIC ])
125 ( 1/2 [MIC ])

8.75 (1/ [MIC ])
17.5 ( 1/2 [MIC ])
1

Tetracycline
Tetracycline
Tetracycline
Tetracycline
Tetracycline
Tetracycline
Tetracycline
Tetracycline
Tetracycline
Tetracycline
Tetracycline

1.25 (+/4 [MIC ])
2.5 (1/2 [MIC ])
0.5 (+/4[MIC ])
1 (1/2 [MIC ]) Tetracycline
1 (1/2 [MIC ]) Ampicillin

Amphiphile

[Antibiotic ] enhance
UM

900
600
82
30
600
200
40
300
400
55
360

+
+
+
+
+
+
+
+
+
+
+

used

ment

100
100
15
8
100
20
5
75
50
5
40

220 + 25
> 1000

n /a
1.5 - fold

55

11 - fold
30 - fold
1.5 - fold

5 - fold
23 - fold
3 - fold

60

2 - fold
16 - fold
3 - fold

4 - fold
0 - fold

65

No amphiphile
Cg hydraphile
Cg hydraphile
Cg hydraphile
C10 hydraphile
C10 hydraphile
C10 hydraphile
C12 hydraphile
C12 hydraphile
C12 hydraphile
C14 hydraphile
C14 hydraphile
C14 hydraphile

Fold

[Amphiphile ]
UM
2.5

50 (1/4 [MIC ])
100 (+/ [MIC ])
2.5
14 (1/4 [MIC ])
28 ( 1/22.5[MIC ])
8.75 (1/4 [MIC ])
17.5 (1/2 [MIC ])
2.5 ( 1/4 [MIC ])
5 (14 [MIC ])
5 (1/2 [MIC ])

Antibiotic
used

[ Antibiotic ] enhance
UM

Tetracycline 1000 = 100
Tetracycline 1000 + 100

ment

n /a
1 - fold

Tetracycline
Tetracycline

250 + 50
25 + 10

Tetracycline
Tetracycline
Tetracycline

900 + 100 1.1 - fold
3 - fold
300 + 50
8 - fold
125 + 25
2 - fold
500 + 50

Tetracycline
Tetracycline
Tetracycline
Tetracycline

300 + 25
125 + 25
350 + 50

Tetracycline 62.5 = 25
Ampicillin

> 1000

4 - fold
40 - fold

3 - fold
8 - fold
3 - fold

16 - fold
0 - fold
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Example 10 : Controls
Example 11: Resistance , Cytotoxicity and
Bioavailability
To better understand the recovery of antibiotic efficacy
observed with hydraphiles, numerous controls were tested
Once it was established that the hydraphiles did recover
against the same strains of bacteria. First , to see if the 5 antibiotic
efficacy against efflux pump expressing resistant
structure of hydraphile was important for the observed bacteria, the
next experiment was to find out if bacteria
recovery of antimicrobial efficacy, the recovery of tetracy
cline activity against Tet E. coli was determined using lariat could develop resistance to the hydraphiles. Sequential
ethers, di benzyl di-aza -crown and quaternary ammonium
culturing method was used to determine if bacteria could
compounds such as C , and C12 trimethylammoniums. Lariat 10 develop resistance to the hydraphiles. As seen in FIG . 15A ,
ethers that differ from hydraphiles because they lack the two Teth E. coli readily developed resistance to minocycline
distal macrocycles did recover tetracycline activity by between
4-6 days. However, the bacteria were not able to
10 -fold . Dibenzyl di-aza -crown that has one macrocycle and develop resistance
past 4 uM to C14 hydraphile for over 15

no alkyl chain linkers did not show any recovery of the
tetracycline activity. Among all the structural variations of 15 days. Hydraphiles are membrane active compounds. Devel

hydraphiles studied, C8- C14 hydraphiles reported herein oping resistance to a membrane active compound would
were the most effective compounds . Tetracycline recovery require multiple changes in membrane composition /synthe
with Cg and C12 trimethylammonium bromides was only 2-4 sis pathways and is energetically less favorable . Such mem
fold at 128 uM ( Table 11), where Cg and C12 hydraphile brane active compounds are associated with cytotoxicity or
showed 30 -fold and 16 -fold recovery at 1/2 MIC concentra- 20
tions. The results suggest that the structure of hydraphile is mutagenicity.
important to observe the recovery of antimicrobial activity
Recent DNA gel electrophoresis study showed that the
and it is not just acting as a quaternary ammonium com hydraphiles at MIC concentrations did not bind DNA . At the
pound that is used as a sterilizing agent in the clinics.
Gramicidin D , valinomycin and Triton X -100 showed concentration of the DNA used for these experiments,
only up to 2 - fold recovery at concentrations of 20 uM . The 25 hydraphile-DNA complexation was observed , but at much
concentrations of these compounds were limited by their higher concentrations than its MIC . Next, the cytotoxicity of
solubility . The results suggest that the hydraphiles did not all the hydraphiles used herein was determined against three
act similar to a dimerized ion channel, an ion carrier or a mammalian epithelial cell lines: HEK -293 , HeLa and Cos -7 .
simple detergent. It is noted that a known ion channel that 30 Colistin and CCCP were used at controls. C8 -C12
does not require to be dimerized in themembrane ofbacteria
would be a better control. The use of Colistin and dapto hydraphiles did show cytotoxicity at MIC concentration to
the HEK -293 cells . However, C14 hydraphile had almost
mycin is addressed below .
Known efflux pump inhibitors (EPI) CCCP (42 uM ) and 80 % survival against HEK -293 cells at MIC concentration
Reserpine ( 128 uM ) recovered the activity of tetracycline by
4 -fold . CCCP dissipates proton motive force required for the
transport of antibiotics by the efflux pumps. Even though
these EPI showed greater recovery than other controls , they
are not as effective as the hydraphiles againstGram -negative
bacteria , which make hydraphiles an attractive alternative .

35

(FIG . 15B ). HeLa and Cos - 7 showed 80-100 % survival

against all the hydraphiles used at MIC concentrations.
However, at 1/2 and 1/4 the [MIC ] of C88 - C14 hydraphiles used

for the synergy study above , minimal cytotoxicity was
observed to the HEK - 293 cells (FIGS. 15E / 15F ). CCCP (a
known EPI) was cytotoxic to all three cell lines.
FIGS. 15E /15F show the cytotoxicity of C8 -C14
hydraphiles at 1/2 and 1/4 the MIC against three mammalian
epithelial cell lines, HEK - 293 , HeLa and Cos- 7. XTT assay

Table 11 represents an important observation . Based on 40
the results of CCCP and reserpine, it was hypothesized that
hydraphiles could disrupt the bacteria membrane integrity
and /or dissipate the cation gradient required for the transport
of antibiotics by active efflux . This hypothesis was tested 45 was used to determine the survival ofmammalian cells in the
below .

presence of synthetic amphiphiles. There was no cytotoxic
ity by C8 -C14 hydraphiles against HeLa and Cos -7. A

TABLE 11

Recovery of tetracycline activity against Terk E. coli by
controls

Amphiphile used
No amphiphile
Dibenzyl diaza crown
Cg trimethylammonium
bromide
C12 trimethylammonium

[ Amphiphile ] [ Tetracycline ]
UM

enhancement

128
128

900 + 100
900
450

n /a
1 - fold
2 - fold

128

225

4 - fold

1
21
42
64

900
450
225
450
225
900 + 100
450 + 100

1 - fold

bromide
CCCP
CCCP
CCCP

Reserpine

Reserpine
Valinomycin

Gramicidin D

Fold

uM

128

Triton X - 100

20
20
20

Triton X - 100

1700 (0.1 % )

450 - 100
450 + 100

2 - fold

minimal toxicity was observed against HEK - 293 cells.
50 Hence , at the sub-MIC concentrations of C8- C14 hydraphiles
that recovery antimicrobial efficacy against resistant bacte
ria , the cytotoxicity to mammalian cells is limited . CCCP
was used as controls .
55

One of the issues with amphiphilic molecules to be used

as antimicrobials is the bioavailability . It was determined if
C14 and C12 hydraphiles were bioavailable in Sprague Daw

4 - fold
2 - fold
4 - fold
1 - fold
2 - fold
2 - fold

60

2 - fold

65

leymice after intravenous injections. Specifically , mice were
injected with 0.5 mg/kg of C12 and C14 hydraphiles . The
plasma concentration of the compounds was measured every
15 minutes using mass-spectrometry. Both C12 and C14
hydraphiles were bioavailable in blood plasma for more than
2 hours after at the concentrations of 100-200 ng/mL ( ~ 85
170 nM ). It is noted that C14 hydraphile was found to
recover tetracycline activity ( in -vitro ) against Teth E. coli at
500 nM . The use of hydraphile -antibiotic combination was
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envisioned for treatment of severely ill patients in the ICU ,

brane permeability of bacterial and mammalian cells was
affected by sub -lethal concentrations of hydraphiles. It was
also determined if hydraphiles could transport potassium
ions from bacteria in the chain length dependent manner.
Example 13 : Mechanism of Efflux Pump

who are infected with MDR bacterial infections. Hence , IV
bioavailability ofmore than 2 hours in plasma is considered
optimal.

5

Example 12 : Efflux Pump Inhibition
Inhibition — Ion Transport
To determine if the activity of efflux pump and accumu
lation of substrate in the cell cytoplasm was affected by
Hydraphiles could cause an indirect inhibition of efflux
hydraphiles , the S. aureus 1199B strain overexpressing the 10 pump activity . Hydraphiles form non-rectifying channels
NorA efflux pump was used . Since ethidium bromide (EB ) that are specific for specific cations . Such channels could
is one ofthe substrates of the norA efflux pump, fluorescence
disrupt ion homeostasis that is required by the efflux pump
from DNA -EB complex was utilized to measure effect of to actively transport antibiotics. C8 -C14 hydraphiles have
hydraphiles on the norA efflux pump. First, EB was added to been reported to transport sodium and potassium ions from
the S. aureus 1199B cells followed by hydraphiles or the 15 liposomes and mammalian cells . However, they have never
controls. If the hydraphiles allows for EB accumulation in been shown to transport cations from bacterial cells .
the cell cytoplasm , an increase in fluorescence would be
The potassium concentration of E. coli cell cytoplasm is
expected . The MIC of C14 hydraphile was observed at 8 uM
against S. aureus (O.D. 600 nm1 = 0.7-0.8 ). As seen in FIG .

200 mM and that of PBS is 4.15 mM . Hence , when
hydraphiles are added to the bacteria and if it forms a

16A, after the addition ofC14 and C12 hydraphile (4 uM ),the 20 non -rectifying channel, the potassium concentration of the

accumulation of EB increases in the cell cytoplasm , regard media surrounding the E. coli cells would increase. This
less of the presence ofNorA efflux pumps. Note that the EB change in potassium ion concentrations was measured using
accumulation by C12 hydraphile at 4 uM was similar to that a Potassium selective electrode. Total potassium content of
of known efflux pump inhibitors CCCP (100 uM ) and the E. coli cells was determined by boiling the cells at 100 °
reserpine (25 ug/mL or 42 uM ). The accumulation of EB by 25 C. The results are represented as the percent of total potas
C14 hydraphile (4 uM ) was greater than twice as much sium content of E. coli released in the presence of
observed with CCCP and reserpine . However , at 4 uM the hydraphiles or controls (FIG . 17A ). Gramicidin D and
activity of CCCP and reserpine was much lower than either valinomycin were used as controls . However , the require
C14 or C12 hydraphiles . Cgand C10 hydraphiles (4 uM ) did ment of gramicidin D to dimerize in the bacterialmembrane
not show any change in the EB accumulation in S. aureus 30 makes an ineffective method for ion transport from bacteria.
1199B cytoplasm . These hydraphiles with shorter spacer Valinomycin acts as an ion carrier rather than a channel.
chain lengths do not span the membrane. As indicated by Hence, no change in ion transport was observed in its
their higher MICs, these compounds might also inhibit the presence . At O.D. 600 nm = 1.3 , the MIC of C14 hydraphile
efflux pump activity at higher concentrations. Next step was against E. coli was 8 uM . The potassium transport ability of
to determine if the accumulation of EB in the cell cytoplasm 35 C8 -C14 hydraphiles was then tested at 4 uM . C14 and C12
was due to the ability ofhydraphiles to inhibit the activity of hydraphile at 4 uM releases approximately 40 % and 25 % of
the norA efflux pump or just a simple membrane disruption the total E. coli potassium ion content from cell cytoplasm
mechanism .
to the cell surrounding , respectively (FIG . 17A ). It is also
In a following experiment, the ability of hydraphiles to known that potassium is released when membrane integrity
inhibit the activity of efflux pumps was determined. Spe- 40 ofbacteria is affected. However , a range of studies has been
cifically, the S. aureus cells were preloaded with EB using reported that prove hydraphiles ' ability to form channels and

100 UM CCCP. The cells were washed to remove extracel
transport ions. It cannot be distinguished if hydraphiles form
channels or disrupt membranes in bacteria . It could be
hydraphiles . If hydraphiles inhibit the activity of efflux argued that hydraphiles would be toxic due to its ability to
pumps, then there should be small or no change in fluores- 45 disrupt ion gradients. Toxicity studies reported above (FIG .
cence of EB -DNA complex . As seen in FIG . 16B , in the 15B and FIGS. 15E /F ) clearly show a minimal cytotoxicity
presence of C10 -C14 hydraphile at 4 uM , there was only of hydraphiles at sub -MIC concentrations used for the
minor change in the fluorescence of EB , indicating an synergy experiments.
inhibition of efflux pump activity . This inhibition was simi
The ion transport ability of hydraphiles was compared to
lar to that of known EPI such as CCCP ( 100 uM ) and 50 thatof tetracycline efficacy recovery against Teth E. coli .As
reserpine ( 41 uM ). When the concentration of CCCP and seen in FIG . 17B , C14 and C12 hydraphiles are the most
reserpine was decreased to 4 uM , inhibition ofNorA activity efficient compounds at both release of potassium ions and
was 30 % lower than that of hydraphiles. However, if there recovery of tetracycline activity . It also became clear that the
is no effect of hydraphiles on the efflux pump activity , EB
ion transport from bacteria and increase in antibiotic potency
would be released resulting in a decrease in fluorescence. Cg 55 by hydraphiles is dependent on its spacer chain length :
hydraphile had only minor effect on the efflux pump activity C14 >C12C102Cg. It is possible that C14 hydraphile is opti
at 4 uM . Higher concentrations of Cg hydraphile might have mal for hydraphiles to span a bilayer membrane of E. coli to
greater effect on efflux pumps. These results confirm the perform its function of ion transport and membrane disrup
inhibition of efflux pump activity and accumulation of tion . Using shorter spacer chain length hydraphiles would
substrate (antibiotics) in cell cytoplasm in the presence of 60 fail to span the membrane , transport ions or disrupt mem
hydraphiles .
brane efficiently . The membrane disruption was tested
Both the accumulation and release of EB from S. aureus below .
1199B in the presence of hydraphiles could be affected by
Example 14 : Membrane Disruption
( 1) the disruption of membrane integrity, which allows for
greater EB accumulation and /or (2 ) uncoupling of the norA 65
efflux pump from ion gradient caused by non -rectifying
A membrane impermeable stain propidium iodide (PI)
lular EB and CCCP. The cells were then treated with

channels formed by hydraphiles . It was tested next if mem

was used to test the membrane permeability of Tet E. coli

US 10,463,044 B2
35

36

by hydraphiles . The permeability of E. coli membrane was

solic content is released in the periplasmic space , forming a

tested at 1/2 MIC of C8-C14 hydraphiles . Triton X - 100 (0.1 % blister/bulge of the outer membrane. Hence , hydraphiles that
Or 1.6 mM ) was used as a control. Fluorescein diacetate disrupted the inner membrane could've formed the blisters
(FDA ) was used as a cell viability stain . Esterase activity of from the outer membrane. Lastly , some bacteria were
viable cells converts FDA to a fluorescent fluorescein . 5 observed with membrane smoothening (FIG . 20C ). It is
Cytoplasmic fluorescence of PI and FDA was observed known that under osmotic stress the water uptake by bacteria
using a confocalmicroscope. As seen in FIG . 18A , E. coli could cause swelling of the bacterial cell. This swelling
alone and DMSO control shows maximum viability and
cause the corrugated membrane to stretch and
minimum membrane disruption . When Triton X - 100 was would
become
smooth . Taken together , these images show that
added , the viability decreased and PI fluorescence increased 10 hydraphiles
aggregates that attach to the bacteria
which indicate a membrane disrupting effect of Triton surface . The formhydraphiles
could both transport ion as
X - 100 . When C8 -C14 hydraphiles were added at 1/2 MIC , observed with membrane smoothening
and. disrupt mem
most of the cells were viable and membrane integrity was branes as observed with membrane blisters
also disrupted as seen by increased PI fluorescence. Here Cg
Having illustrated and described the principles of the
and C1o hydraphiles may seem to show greater increase in 15 present
invention , it should be apparent to persons skilled in
permeability than C12 and C14 hydraphiles . This could be the art that
the invention can be modified in arrangement and
due to the fact that 1/2 MIC of Cg and C1o hydraphiles are detail without
departing from such principles. Those skilled
much higher than other hydraphiles used .
in
the
art
will
recognize , or be able to ascertain using no
It could be argued that hydraphiles could also localize and more than routine
experimentation , many equivalents to the
disrupt the mammalian cell membranes . The effect of 20 specific embodiments
of the invention described herein .
C8 -C14 hydraphiles on the membrane integrity ofmamma Such equivalents are intended
to be encompassed by the
lian HEK -293 cells was then tested , see , FIGS . 18B - 18C , following claims.
which demonstrate the permeability of HEK -293 mamma
publications and published patent documents cited in
lian cells in the presence of 1/2 MIC and 2 [MIC ] of C8- C14 thisAllspecification
are incorporated herein by reference to the
hydraphiles . These hydraphiles increased the permeability 25 same
extent
as
if each individual publication or patent
of E. coli cells at 112 MIC concentrations. However, they application was specifically
failed to increase the permeability ofHEK -293 mammalian incorporated by reference . and individually indicated to be
cells at 2x [MIC ] concentrations. At 0.1 % or 1.6 mM , Triton
X - 100 killed all the HEK - 293 cells and disrupted mem
is claimed is :
branes showing high PI fluorescence . However, the viability 30 What
1.
A
method
the resistance of a multi -drug
was high and minimal PI fluorescence was observed with 1/2 resistant bacteriumof reversing
to an antibiotic by inhibiting efflux pump
MICs of C8-C14 hydraphiles. The results show that at 1/2 activity
in the multi-drug resistant bacterium , said method
MIC the hydraphiles disrupted bacterial membrane but did comprising
administering to said bacterium the antibiotic
not affect mammalian membranes . It was confirmed that
and
a
synthetic
amphiphile, wherein said synthetic amphi
even at MIC concentrations, the hydraphiles failed to affect 35 phile is a hydraphile
comprising the structure of Formula 4 ;
the HEK -293 mammalian cell membrane integrity. It is
concluded that C8 -C14 hydraphiles can selectively increase
the permeability of bacterial cells without affecting the
Formula 4
permeability of mammalian cells. Cg hydraphile was not
used beyond 125 uM for solubility reasons. DMSO and 40
Triton X - 100 were used as controls .

To confirm if Cg and C14 hydraphile both affect the
membrane integrity of individual bacterial cells , scanning
electron microscopy was used . Specifically , the Tet" E. coli
cells were treated with 1/2 MIC of C , and C14 hydraphiles, 45
loaded on to a membrane , fixed and stained before observing
under a SEM ( FIG . 19 ). Under the amphiphile alone column ,
membrane background (top ) and an aggregate formed by
C14 hydraphiles in the absence of bacteria was observed .
Similar aggregates were observed with Cg hydraphiles. In an 50
untreated E. coli cell, the membrane was corrugated and no
membrane disruption or aggregates were apparent. When
the E. coli was treated with hydraphile alone or hydraphile +
tetracycline, the following three key features were observed

N- (CH2)n - N

N

- (CH2)n

55
with both Cg and C14 hydraphiles .
First, uniform , well-formed aggregates of hydraphiles of
approximately 100-120 nm was observed on the surface of
E. coli (FIG . 20A ). Hydraphiles may form uniform 100-200
nm aggregates before attaching and inserting to the E. coli
wherein n is 8 , 10 , 12 , or 14 ; and wherein said
membranes. Alternatively , these aggregates may have also 60
hydraphile is administered at a concentration of half or
formed after the disruption of E. coli membrane . In such
less of its minimum inhibitory concentration (MIC )
case, these aggregates may comprise of a mixture of E. coli
against the multi -drug resistant bacterium as deter
mined in the absence of the antibiotic .
membrane lipids and hydraphiles. Secondly , irregular blis
ters were observed on the surface of E. coli membranes
2. The method of claim 1 , wherein said synthetic amphi
(FIG . 20B ). These blisters were distinct from the hydraphile 65 phile is administered as an aggregate or in a liposome
aggregates observed next to the blisters on the bacteria . It is
3. The method of claim 1 , wherein said synthetic amphi
known that if cytoplasmic membrane is disrupted , the cyto phile is administered in a protonated or salt form .
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4. The method of claim 1 , wherein said bacterium is a

bacterium in the family Enterobacteriaceae, in the family

Bacillaceae , or in the family Pseudomonadaceae .
5. The method of claim 4 , wherein said bacterium is an
efflux pump expressing Gram -positive or Gram -negative 5
bacterium .
6. The method of claim 1 , wherein the antibiotic is
administered at a concentration lower than its minimum

inhibitory concentration (MIC ) against themulti-drug resis
tant bacterium as determined in the absence of the synthetic 10

amphiphile.
7. The method of claim 1, wherein
administered at a concentration of 1 nM
8. The method of claim 6 , wherein
administered at a concentration of 1 nM

the hydraphile is
to 10 UM .

the hydraphile is
to 10 uM .

15

